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Abstract: Clinical trials conducted in low-resource settings have unique challenges associated with their
conduct. This is mainly attributed to the power and resource discrepancy between actors in the clinical
trial. This thesis provides an in-depth look at clinical trials in low-resource settings and the effects of the
resource discrepancy on the actors. It aims to answer what the ethical challenges are when conducting
research in low-resource settings and the subsequent implications for research design. It focuses on
capturing both the experience of caregivers of pediatric participants and the frontline researchers in a
malaria vaccine clinical trial. Through exploring these two stories and bridging the relational with the
formal, it provides a novel approach to address the challenges with research in low-resource settings.
This approach employs the lens of complexity theory to evaluate the outcome of two systems, a human
community and a clinical trial, merging. I will begin by outlining a general introduction of clinical trials
in low-resource settings and the case study of a pediatric malaria vaccine clinical trial, here I detail the
need to generate a vaccine against malaria and outline why such research should take place. This situates
the reasons for the study and provides familiarity with the contextual reality. Then I will move into
detailing the caregiver experiences, researcher experiences, and the application of complexity theory to
bridge together the different experiences. This thesis is a result of qualitative data gathered from 78
interviews with caregivers of pediatric participants and 11 interviews with researchers involved on the
frontline of a pediatric malaria vaccine clinical trial. The final part of the thesis is a theoretical reflection
that explores the realities faced by researchers and argues for an approach that embraces the non-linearity
of research taking place in human communities. Here I identify the challenges associated with choice and
structural inequity, the conflict between beneficence and autonomy, and being a frontline researcher in
low-resource settings.
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Clinical trials conducted in low-resource settings have unique challenges associated with their 
conduct. This is mainly attributed to the power and resource discrepancy between actors in the 
clinical trial. This thesis provides an in-depth look at clinical trials in low-resource settings and the 
effects of the resource discrepancy on the actors. It aims to answer what the ethical challenges are 
when conducting research in low-resource settings and the subsequent implications for research 
design. It focuses on capturing both the experience of caregivers of pediatric participants and the 
frontline researchers in a malaria vaccine clinical trial. Through exploring these two stories and 
bridging the relational with the formal, it provides a novel approach to address the challenges with 
research in low-resource settings. This approach employs the lens of complexity theory to evaluate 
the outcome of two systems, a human community and a clinical trial, merging.  
 I will begin by outlining a general introduction of clinical trials in low-resource settings 
and the case study of a pediatric malaria vaccine clinical trial, here I detail the need to generate a 
vaccine against malaria and outline why such research should take place. This situates the reasons 
for the study and provides familiarity with the contextual reality. Then I will move into detailing 
the caregiver experiences, researcher experiences, and the application of complexity theory to 
bridge together the different experiences. 
 This thesis is a result of qualitative data gathered from 78 interviews with caregivers of 
pediatric participants and 11 interviews with researchers involved on the frontline of a pediatric 
malaria vaccine clinical trial. The final part of the thesis is a theoretical reflection that explores the 
realities faced by researchers and argues for an approach that embraces the non-linearity of 
research taking place in human communities. Here I identify the challenges associated with choice 
and structural inequity, the conflict between beneficence and autonomy, and being a frontline 
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Clinical trials in low-resource settings  
 
 The establishment of the Nuremburg code in 1948 stating that “The voluntary consent of 
the human subject is absolutely essential” formalized research ethics and advocated for informed 
consent and balanced risks and benefits in medical research. This first international document 
paved the way for subsequent recommendations - notably the Declaration of Helsinki, the Belmont 
Report, the Council for International Organizations guidelines (CIOMS) – as well as various other 
national and institutional ethics standards that provide guidance on medical research today 
(Council for International Organizations of Medical Sciences & World Health Organization, 2002; 
National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research, 1978; World Medical Association, 2013).  Despite the existence of these foundational 
documents, context-dependent ethical challenges continue to arise. Clinical trials in low-resource 
contexts have unique ethical challenges associated with their conduct due to the inequity of power 
and resources. When a clinical trial is launched in a low-resource setting, involving local 
communities, specific ethical challenges can be intensified by the inequity between actors. In this 
project I will investigate these ethical implications through a case study using a pediatric malaria 
vaccine trial (PMVT).  
 
A pediatric malaria vaccine as a case study 
 
 I have chosen to use the RTS,S malaria vaccine phase III clinical trial as a case study for 
this project as it was a transnational trial, conducted across health and social systems (RTS,S 
Clinical Trials Partnership, 2015a). Due to the size and length of the trial it is particularly suited 
to studying the experiences of different actors in the clinical trial and the accompanying ethical 
implications. In the next part I will spend some time describing the PMVT by introducing the 
disease context, vaccine aims and development process to highlight the human realities in research 
such as the RTS,S phase III clinical trial.  
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Why a malaria vaccine? 
 
 In 2017 malaria was attributed to 435 000 deaths and nearly half the world’s population 
was identified to be at risk of infection. Malarial disease carries an immense public health burden,   
and those at the highest risk for malaria are children living in endemic regions; it is estimated that 
266 000 children died from infection in 2017 (WHO, 2018b).  There are many intervention 
methods available, such as insecticide-treated bed nets, vector control and anti-malarial therapy, 
but those are not likely to lead to the rapid elimination of the disease (Rowe et al., 2007). In order 
to achieve the reduction of malaria incidence by 90% as outlined in Global Technical Strategy for 
Malaria 2016-2030, more tools are needed, including effective vaccines, especially in high 
transmission areas such as sub-Saharan Africa (World Health Organization, World Health 
Organization, & Global Malaria Programme, 2015). Today there is cautious optimism for a 
modestly effective vaccine called RTS,S developed in partnership by PATH Malaria Vaccine 
Initiate (MVI) and GlaxoSmithKline (GSK).  
 
 Due to the high burden of disease, a vaccine with a modest level of protection would 
translate into a significant impact given almost half a million annual deaths. Based on phase III 
studies that were carried out with RTS,S in conjunction with intervention methods, severe malaria 
cases were cut by one third (RTS,S Clinical Trials Partnership, 2015a).  RTS,S has been shown to 
be most effective in children aged 5-17 months, who receive three doses of the vaccine and then a 
booster at 20 months of age, reducing the cases of severe malaria by 36% (Agnandji et al., 2012). 
In October of 2015 the WHO approved pilot testing of RTS,S for children in this age group (WHO, 
2017b). 
 
 For immunological reasons it is very difficult to create an effective vaccine for malaria and 
RTS,S is at least 10 years ahead of all other vaccine candidates (Ballou, 2009).  It targets the pre-
erythrocytic state of Plasmodium falciparum, the malaria parasite with the highest burden of severe 
disease, by training the host’s immune system to detect the parasite in the sporozoite stage – 
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triggering an immune response before infection of the liver or red blood cells (Sauboin, 
Bellinghen, Velde, & Vlaenderen, 2015). The vexing burden of malaria mortality and morbidity 
can silence ethical concerns that surround a modestly effective vaccine, yet previous well-intended 
elimination attempts have taught us to carefully consider the long-term consequences of such an 
endeavor (Byass, 2008; Ceesay et al., 2008; O’Meara et al., 2008).  
 
 Prosaic challenges common to vaccination in developing countries are also faced by 
RTS,S. It requires refrigeration, a particular problem in rural areas, and adds two medical visits to 
the routine vaccination schedule. Cold-chain management, preventing donor fatigue, and a feasible 
vaccination schedule are obstacles that require further clarification (Graboyes, 2015; Gulland, 
2015). In addition to these pragmatic concerns, questions unique to malaria arise, such as how long 
the vaccine provides protection and if it reduces mortality or merely delays it. Malaria has co-
evolved with humans for over 100 000 years and we have developed various traits to favour 
survival. Among these is acquired immunity, which develops in the first five years of life, the 
period of time where malaria carries the highest mortality rates. RTS,S targets this age group 
specifically to reduce the mortality, but potentially jeopardizing the acquisition of acquired 
immunity as a consequence. This has the potential to shift malaria epidemiology from a stable to 




MALARIA VACCINE ETHICS 
 
 The outlined challenges are not insurmountable but do call for vigilant researchers 
committed to long-term monitoring of the vaccine research sites. Clear commitments to 
community involvement and publicly stated research goals will contribute to this process. To best 
support local researchers in this endeavor we need a better understanding of the local experiences 
and the accompanying ethical challenges. That is the aim of the empirical research conducted in 
this project, outlined in paper two, three and four. Before we explore that, we first need to position 
RTS,S in relation to the principles which lay the ethical foundation for clinical trial conduct. Next, 
we will outline these and systematically delineate some early questions relevant to these principles.  
 
Principle-based research ethics 
 
 The Belmont report from 1979 acknowledged four foundational principles for research 
ethics: respect for autonomy, beneficence, non-maleficence, and justice (National Commission for 
the Protection of Human Subjects of Biomedical and Behavioral Research, 1978). These principals 
are the foundation of biomedical ethics and lay the groundwork for ethical research (T. L. 
Beauchamp & Childress, 2009).  
 
Respect for autonomy 
 
 Respect for autonomy ensures that individuals are able to make informed decisions 
voluntarily about participation in research studies. Obtaining informed consent is often singled out 
as the principle on which ethical research hinges, but empirical research shows that it is often not 
done as it should (Emanuel, Wendler, Killen, & Grady, 2004). Differences in language, social 
traditions, and practices complicate obtaining informed consent in regions such as sub-Saharan 
Africa (Fadare, Ademowo, & others, 2010). It is a process and must be carried out as such, yet has 
increasingly grown into a means to an end – with the focus on forms and processes – as opposed 
to securing informed, understanding and voluntary participation (Graboyes, 2015). The 
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foundations to ensure respect for autonomy in the sub-Saharan region are laid by the Declaration 
of Helsinki (World Medical Association, 2013) and CIOMS guidelines (Council for International 
Organizations of Medical Sciences & World Health Organization, 2002). However, this should 
also be viewed through the prism of RTS,S realities which includes pediatric subjects, collective 
societies and developing world contexts.  
 
 A challenge encompassing the voluntary nature of consent in RTS,S research is the 
vulnerable pediatric population it targets. Minors are unable to provide legal consent and parents 
are called upon to provide it on their behalf, many of whom may have a limited understanding of 
the terms informed consent and confidentiality (Kulkarni, 2013).  Recent ethical guidelines have 
proposed a coupling of parental consent with participant’s ‘assent’ to protect the young population 
enrolled; a potential tool for older participants (Council of Europe, 2007; Fadare et al., 2010). By 
exhibiting sensitivity to the local context and utilizing local language, culturally appropriate 
idioms, and analogies that are commonly used in the local culture these confounding factors can 
be minimized (Kithinji & Kass, 2010).  
 
 Within the collective social systems where RTS,S research takes place, community 
engagement and family structures differ from the West - where individual autonomy reigns. This 
communitarian way of life means that obtaining informed consent entails “spheres of consent” 
involving village elders, leaders of extended families, or heads of households who are often 
required to consent prior to the parents of the participants (IJsselmuiden & Faden, 1992; Weijer & 
Emanuel, 2000). The majority of bioethics takes place in the developed world, creating a cultural 
bias in the guidelines overlooking this key aspect of collectivistic societies (Gikonyo, Bejon, 
Marsh, & Molyneux, 2008). However Kenya, South Africa(Langlois, 2008) and Nigeria 
(Adebamowo, Mafe, Yakubu, Adekeye, & Jiya, 2008; Nigeria Ministry of Health, 2007) have 
called for researchers to strengthen community participation by outlining it in their research ethics 
guidelines. Strong community relations and local engagement brings autonomy, transparency and 
respect to the work of the researchers, but also from a utilitarian perspective, it will strengthen the 
community’s relationship in the long-term with research. Thus, the questions that have remained 
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largely unexplored with regard to respect for autonomy in clinical trial research through the lens 
of RTS,S are:  
 
1. Are all options explored to ensure transparency when faced with communication 
challenges? 
2. Who is responsible for ensuring that consent obtained is truly informed?  
3. How are parents informed and how do they formally consent?  
4. Is community engagement occurring and are local customs respected? 
5. Are individual participants being informed through community outreach?  
6. Are individuals opting out of the study treated respectfully? 
 
Beneficence and non-maleficence  
 
 To adhere to the principles of beneficence and non-maleficence, those involved in the 
execution of clinical trials must have the welfare of the participants as the goal of the study. The 
creation of a new malaria vaccine is a benevolent act, however unintentional harm may coincide 
with its implementation. Malaria epidemiological patterns are difficult to predict in response to 
intervention, and historical records from research carried out in endemic regions provides evidence 
for resurgence and, in some cases, shifts from a stable to an unstable disease pattern (Carneiro et 
al., 2010; J. M. Cohen et al., 2012; Fadare et al., 2010; Graboyes, 2015). In malaria endemic 
regions, the risk of mortality shifts to morbidity at around age five. However, preliminary evidence 
from the WHO suggests that severe malaria is starting to occur at later ages in children living in 
RTS,S research sites (Malaria Vaccine Funders Group, 2013). This places an emphasis on the need 
for long-term monitoring and evaluation of research sites following the conclusion of a vaccine 
clinical trial (Snow et al., 1997).  
 
 Vaccination campaigns often argue that for the greater good, on the grounds of herd 
immunity, those eligible for vaccination are obliged to do so – carrying a heavy dose of 
paternalism. Herd immunity stipulates that if the majority of the population is protected from a 
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disease (vaccinated) there is a reduction in disease circulation, thereby conferring protection to 
those unable to be vaccinated (Hendrix, Sturm, Zimet, & Meslin, 2016). As RTS,S only provides 
modest, waning protection, there is no significant herd immunity. Additionally, the benefit: harm 
ratio is higher than with most other childhood vaccines which are 90%-99% effective. With RTS,S 
64% of children will be exposed to the potential harm of vaccination without a perceived benefit. 
Additionally the mortality rates are higher amongst girls enrolled in the clinical trials than boys 
(Klein, Shann, Moss, Benn, & Aaby, 2016; WHO, 2016). As such, the potential harm RTS,S 
participants are exposed to must be carefully balanced with public health goals - and to better 
understand these harms, long-term commitments from researchers and funding bodies are required.  
 
 In summary, a vaccine which reduces the burden of malarial disease through protecting 
those most vulnerable to severe disease is providing a benefit to the local population (Alonso, 
2006). However, the thorny dynamics of malarial disease call into question the unforeseen long-
term consequences of such an endeavor and demand closer epidemiological monitoring. The 
questions that I thus consider to be most important with regard to beneficence and non-maleficence 
are:  
1. Are participants exposed to an unfair level of risk? 
2. Are researchers committed to monitoring the causes of mortality and the accompanying 
epidemiology? 
3. Are historical events informing the modern day RTS,S research studies? 
4. Are researchers responding to the WHO’s identification of the safety signal linked to 




 The principle of justice in bioethics calls for all individuals to be treated equally, that one 
society does not have to carry the burdens of another (Kruger, Ndebele, & Horn, 2014). A malaria 
vaccine will have a major impact on public health in sub-Saharan Africa, yet safe development 
and equitable access to such a vaccine is hugely impacted by resource availability (J. Cohen, 
Nussenzweig, Vekemans, & Leach, 2010; Penny et al., 2016). The vaccine is being tested in 
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endemic regions, reflecting the health needs of the region, an important component of localized 
medical research. Yet members of rural communities where RTS,S research takes place often have 
little political power, education, knowledge of medical interventions, resources and have a dire 
need for medical care – enhancing the vulnerability of the participants to exploitation (Glantz, 
Annas, Grodin, & Mariner, 1998).  
 
 As the malaria vaccine transitions out of clinical trials and into pilot studies the needs of 
the local communities must be balanced with the wishes of the researchers (Graboyes, 2015). The 
principle of justice calls on us to work towards reducing the burden of malaria in the developing 
world through increasing access to interventions and developing new methods to do so; both of 
which require resources from high-income countries and donor organisations (Jamrozik, Fuente-
Núñez, Reis, Ringwald, & Selgelid, 2015). Inter alia, it requires us to share the burden of malaria 
and conduct vigilant research committed to the well-being of local people, preventing further 
impoverishment of the families and communities. The questions that I thus consider to be most 
important with regard to justice are:  
1. Are participants being recruited in a fair and just way? 
2. Are long-term financial commitments in development? 
3. What are the responsibilities of the researchers now that the clinical trials have completed? 
4. If the participants are carrying the burden of being enrolled in the study, are their 
communities prioritized as implementation settings? Should the costs be subsidised?  





 Where the foundation in biomedical ethics rests on the principles outlined above, when it 
comes to research involving human communities the critical piece of human relationships also 
comes into play. Specifically, relationships that form during the years that the clinical trial is active 
in a community. Part of the investigation in this thesis will focus specifically on the relationship 
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between participants and their caregivers with the research team conducting the trial. Relational 
ethics is an important aspect to consider during interactions between these actors. Relational ethics 
runs on the premise that ethical judgements are made in the context of relationship and therefore 
needs to be recognized as a morally significant player in the decision-making process (Sherwin, 
1992). This moves beyond the principles outlined above, where the participant and researcher are 
viewed as strangers. Instead, one recognizes that researchers may experience moral distress when 
trying to balance their obligations to sponsors or research institutions with their moral duty to the 
caregiver and participant.  
 
 Where principal-based ethics, or formal ethics, provides a foundation on which we can 
review research protocols, relational ethics allows for a more expansive interpretation that is 
situated in the context of the trial stakeholders. Relational ethics can therefore play two roles. One, 
it can help us understand the principles and their applications, for instance how autonomy can be 
interpreted based on the relational context in which they are applied. And second, relational ethics 
can mean being in relation with someone and the generation of duties to that person which 
correspond with the relationship. This falls outside of the ethics of principalism and creates a 
genuine source of further duties or obligations.  
 
 Some of the aspects I will investigate through the case study are the decision-making and 
consent processes, the embodied reality of the researcher and the presence of power dynamics. 
The notion of relational ethics runs through relevant principles such as solidarity, benefit-sharing, 
embodied accountability and relational duty. Solidarity can be used as a way to recognize that any 
human actor and their identity is shaped by their social interactions. I look at benefit-sharing as a 
call for the actors involved to reflect mutual-respect in the benefits accrued by each group. The 
role of embodied accountability outlines actor decision-making as multi-dimensional, depending 
on cognitive, affective and emotional experiences. Finally, relational duty serves as a way to 
acknowledge power differentials, based on the norms of equity and complementary reciprocity, 
having responsibility to one another and recognizing power discrepancies without the exclusion of 
the other (Pollard, 2015).   
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THE BROADER PICTURE 
 
The case study and clinical trials in low-resource settings 
 
 Above I have outlined the details of the case study, why the PMVT serves as a useful case 
study to investigate clinical trial conduct in low-resource settings, and the foundational ethical 
principles and their relevance to the PMVT. I have chosen to focus on the bioethical principles as 
a starting block as we base our institutional reviews of clinical trial protocol on these. With these 
fundamental principles as a foundation, I will build my investigation into the ethical challenges 




 The research objective is to identify the ethical challenges and corresponding implications 
for future clinical trials in low-resource settings using the RTS,S malaria vaccine as a case study. 
Taking the considerations above, the original research conducted during this PhD project aimed to 
capture the perspective of both the caregivers of pediatric participants in the clinical trial and the 
research team in the PMVT. The four papers that follow move through these topics in the following 
ways.  
 
 The first paper, RTS,S malaria vaccine pilot studies: addressing the human realities in 
large-scale clinical trials, is a commentary on the RTS,S clinical trial and outlines the clinical trial 
experiences in relation to the upcoming pilot implementation. It explores the relationship between 
researchers, participants and the communities where the research takes place. Based on this 
exploration, recommendations are made with regards to the pilot study implementation and clinical 
trial design for low-resource settings.  
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 Following this introduction into the PMVT, the second paper, Clinical trials in low-
resource settings: the perspectives of caregivers of paediatric participants from Uganda, Tanzania 
and Kenya, is a result of empirical research aimed at understanding the caregiver experience in a 
PMVT. The data collection involved 78 in-depth interviews with parents of children enrolled in 
the RTS,S malaria vaccine phase III study or, as a control, the GMZ2 malaria vaccine phase IIb 
study. Through speaking to caregivers and inquiring about their experience consenting on behalf 
of the pediatric participant as well as the overall research experience, a deeper assessment of the 
ethical challenges experienced by this group of actors (caregivers) can be made.  
 
 I begin by presenting this empirical data reflective of the caregiver experience and follow 
it with the third paper, which investigates the researcher experience. As the caregivers introduce 
the challenges associated with clinical trials in low-resource settings, the researchers provide their 
perspective and experience. I frame the researcher experience using complexity theory, 
highlighting that when clinical trials enter the community, they form one complex adaptive system 
(CAS) together. This third paper is the result of twelve qualitative in-depth interviews with 
members of the RTS,S malaria vaccine phase III clinical trial in Kenya. Here I identify the main 
challenges researchers experience when working in the community and the ways in which they 
deal with this.  
 
 In the fourth paper I bring together the experience of the researcher and the caregiver 
explored in the earlier papers and formulate simple rules that govern the clinical trial system. These 
are based on the interviews with both caregivers and members of the research team and serves to 
frame the ethical challenges around a CAS model.  
 
 The final theoretical discussion looks to explore the ethical challenges in further detail as 
well as recommend ways in which to respond, the implications for research and the duties 
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ABSTRACT 
 
A malaria vaccine as part of the integrated malaria control and elimination efforts will have a 
major impact on public health in sub-Sahara Africa. The first malaria vaccine, RTS,S, now enters 
pilot implementation in three African countries. These pilot implementation studies are being 
initiated in Kenya, Malawi and Ghana to inform the broader roll-out recommendation. Based on 
the malaria vaccine clinical trial experiences, key ethical practices for effective clinical trial 
research in low-resource settings are described. For successful vaccine integration into malaria 
intervention programs, the relational dynamics between researchers and trial communities must 
be made explicit. Incorporating community values and returning to research practices that serve 
the intended benefactors are key strategies that address the human realities in large-scale clinical 







In 2017 malaria was attributed to 435 000 deaths and nearly half the world’s population was 
identified to be at risk of infection. Malarial disease carries an immense public health burden,   
and those at the highest risk for malaria are children living in endemic regions; it is estimated 
that 266 000 children under five years of age died from infection in 2017 (WHO, 2018b). Since 
the year 2000 significant work has been done towards reducing the burden of malaria, with much 
progress made (Bhatt et al., 2015). This success is largely owed to insecticide treated bed nets 
(INTs), indoor residual spraying (IRS) and artemisinin-based combination therapy (ACTs) also 
contributing to a 40% reduction in clinical disease and a 50% reduction in Plasmodium 
falciparum infection (Bhatt et al., 2015). While these figures looked promising, they were still 
far short of the WHO target of 75% reduction in malaria burden by the year 2015 (Roll Back 
Malaria Partnership/World Health Organization, 2008). In order to achieve this reduction, more 
tools are needed – including effective vaccines, especially in high-transmission areas.  
There are currently a number of vaccines in the pipeline for malaria, in both pre-clinical and 
clinical development, targeting both children and pregnant women (WHO, 2017c)(4). These 
target varying stages of the malaria parasite’s life-cycle and are categorised as pre-erythrocytic 
vaccines (PEV), blood-stage vaccines (BSV), transmission-blocking vaccines (MSTBV) and 
combination vaccines. Despite a robust pipeline, long-lasting sterile immunity against malaria 
with these vaccines is unlikely and a vaccine will instead serve as a tool to be utilized in 
combination with other intervention methods. Due to the high burden of disease, a vaccine with a 
modest level of protection would translate into a significant impact given almost half a million 
annual deaths. Today there is cautious optimism for a modestly effective vaccine called RTS,S 
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developed in partnership by PATH Malaria Vaccine Initiate (MVI), GlaxoSmithKline (GSK) and 
a number of academic and research institutions.  
RST,S is a pre-erythrocytic vaccine that has been in development since 1987 and concluded 
phase III testing in early 2014. The phase III studies adhered stringently to all aspects of formal 
research requirements, such as Good Clinical Practice (GCP) and Good Laboratory Practice 
(GLP) guidelines; every effort was made to standardize the process. This large multi-national 
trial enrolled 15 459 infants and was carried out at 11 clinical trials centres in 7 countries 
(Burkina Faso, Gabon, Malawi, Mozambique, Ghana, Tanzania, Kenya). RTS,S has been shown 
to be most effective in children aged 5-17 months, who receive three doses of the vaccine and 
then a booster at 20 months of age, reducing the cases of severe malaria by 36% (RTS,S Clinical 
Trials Partnership, 2015a).  
The next step for this vaccine is pilot study roll-out in Kenya, Ghana and Malawi. In these three 
selected countries the Ministries of Health will work together with the WHO to establish the 
Malaria Vaccine Implementation Program (MVIP).  In addition to the efficacy and safety profile, 
these pilot implementation studies will shed light on the programmatic feasibility of RTS,S in 
real-life settings, a factor modelling studies have identified to be a critical component of reaching 
a significant public health impact (Galactionova et al., 2017; Penny et al., 2016).  To adequately 
assess the feasibility of RTS,S in real-life settings, researchers must engage local communities 
and carefully consider the ethics and processes of undertaking MVIP in different sociocultural 
settings. This means acknowledging relational ethics in vaccine studies, community dynamics 




THE ROLE OF RELATIONSHIP IN RESEARCH STUDIES  
 
Previous RTS,S studies have placed a lot of emphasis on adhering to regulatory requirements 
and formal research ethics. What we can learn from other vaccine trials is that the emphasis of 
formal research ethics is as important as close engagement of the clinical trial team with the 
community (P. Wenzel Geissler, Kelly, Imoukhuede, & Pool, 2008).  Taking the time to build 
intimate relationships fostering shared ownership of the research synergistically and effectively 
complements the scientific protocols and formal ethical procedures. Relational ethics and shared 
ownership play a significant role in determining the effectiveness of malaria vaccine studies. 
Much of the success of a malaria vaccine trial in The Gambia has been attributed to intimate 
kinship-like relationships between the trial community and field workers (P. Wenzel Geissler et 
al., 2008). This kind of a relational interaction fosters close collaboration between researchers 
and communities to confront social and political circumstances. Through this interaction it was 
found that even in contexts where parental awareness of the RTS,S vaccine was low, there 
remained a keen desire to enrol children in RTS,S vaccination programs if made available. Based 
on this work, recommendations have been made around disseminating information specifically to 
mothers about the vaccine that considers the social and political realities that participants inhabit 
(Romore et al., 2015). In Tanzania, stakeholders have expressed a positive opinion of the vaccine 
but have drawn attention to the need for an inclusive communication strategy that incorporates 
communities and local health care professionals in a culturally appropriate way for that positive 
opinion to endure (Mtenga et al., 2016). These examples shed light on the need to critically 
assess processes and ethical conduct during large-scale clinical trials to ensure effective 
incorporation of the tool into integrated malaria control and elimination programs; considerations 
that stretch beyond a confident safety profile.   
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The international community has set ambitious goals for malaria by 2030 and has put RTS,S on 
the table as a tool to be used in an integrated approach with other malaria interventions (World 
Health Organization et al., 2015). As we move forward these relational aspects are of particular 
importance to foster a concerted effort across scientific disciplines and stakeholders from varying 
sociocultural backgrounds. By harnessing lessons learned from previous malaria vaccine clinical 
trial experiences, effective integration of this vaccine into malaria control programs is possible in 




COMMUNITIES AND VACCINE UPTAKE 
 
Strong community relations and local engagement has the potential to bring autonomy, 
transparency and respect to the work of the researchers. From a utilitarian perspective, it can 
strengthen the RTS,S malaria pilot study in the selected sites. The RTS,S phase III studies had 
Community Advisory Boards (CABS) which consisted of influential community members who 
supported the communication between communities and researchers. These have been effective 
and therefore need to be further strengthened to involve additional stakeholders with interests in 
the community and the children’s welfare at large (Shubis, Juma, Sharifu, Burgess, & Abdulla, 
2009). Acknowledging fundamental intelligence within communities and translating this into the 
execution of these pilot implementation studies will propel us toward the goal of RTS,S 
informed choice and acceptance within the community setting. Listening to the voices of the 
community and integrating these into the study design leads to greater research vaccine uptake 
(Duan, 2005; Lavery, 2018; Pratt & de Vries, 2018). Failure to do so heightens the power 




LONG-TERM MONITORING OF STUDY SITES 
 
In malaria endemic regions, the risk of mortality shifts to morbidity at around age five. However, 
modeling studies suggest that severe malaria is likely to occur at later ages in children living in 
RTS,S research sites (Penny et al., 2016). This places an emphasis on the need for long-term 
monitoring and evaluation of research sites. This sustained long-term monitoring is often 
resource consuming but is critical in understanding the impact of interventions and shifting 
disease epidemiology. Through the collection of narratives and genuinely engaging with 
community members to share their experiences, potential risks can be followed-up, flagged and 
clinically investigated. Ethical conduct does not only conclude at obtaining informed consent, it 
continues into research, monitoring and implementation. The transition in age for severe malaria 
needs to be explained to the communities – that it is not related to the vaccine deployment but 
rather a change in the disease prevalence. This, if not explained well, may affect the uptake of 
the vaccine over time. 
Some may challenge the feasibility of relational engagement that is context-sensitive to the 
MVIP sites, however substantive evidence indicates that close community engagement is a 
favourable approach to the research in question and does not introduce biases and dependencies 
of concern at the ethical or research outcome levels (ENDA Graf Sahel, 1993; Jagosh et al., 
2012; Lantz, Israel, Schulz, & Reyes, 2017; Rhodes, Malow, & Jolly, 2010). We therefore argue 
that this can be streamlined and, on the contrary, strengthen the efficiency of the pilot studies. 
Communities can always provide key insights and facilitate researcher familiarization with the 
research setting. This, in turn, allows for effective planning and site organization, two factors that 
have been identified to be key contributors to streamlining the efficiency of clinical trials 
(Vischer, Pfeiffer, Limacher, & Burri, 2017). Through encouraging dialogue during initial 
 37 
introductions and building relationships that encourage communities to speak up, to feel safe 
when doing so, and report when adverse events occur – time will be saved and researchers can 
ensure a more benevolent process as the monitoring is intrinsic to the study. Previous studies 
looking at the benefits of community engagement support these claims, suggesting enhanced 
ownership of the research by local communities strengthens the effectiveness of the research 
(Gikonyo et al., 2008, 2013; Nyika et al., 2010; Wendler & Shah, 2015). Combating the thorny 
dynamics of malarial disease without this approach can lead to the aggravation of adverse events 
and mistrust in the community of vaccination research as a whole (Gikonyo et al., 2008; Nyika et 
al., 2010). Therefore, it is the responsibility of those who will conduct the pilot implementation 
studies to call upon the communities to work alongside them for support when incorporating the 
distinctive values, social and cultural practices to build trust and ultimately strengthen the social 




Reaching coverage across the target population and creating an integrated, tailored approach 
alongside other malaria interventions will determine the extent of the public health impact a 
malaria vaccine will have (J. Cohen et al., 2010; Penny et al., 2016). This means a keen 
awareness of local prevention and treatment practices as well as transmission patterns. Vaccines 
in the development pipeline targeting parasitic diseases cannot be compared to the well-known 
highly efficacious vaccines of the childhood diseases caused by bacteria and viruses. Parasites 
have very complex, virtuous life cycles with sexual and asexual development cycles in different 
niches of the hosts and thus current efforts lead to only partially efficacious vaccines, that still 
show a significant alleviation of the disease burden (Delany, Rappuoli, & De Gregorio, 2014). 
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Consequently, working with partially effective vaccines, and tools in general, heightens the 
emphasis we must place on rooting research in the local social realities to best understand 
compliance and adherence. RTS,S has an excellent opportunity to set the global stage for shared 
research ownership, effective community engagement and the development of an integrated, 
tailored approach to reduce the disease burden.  
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Objectives: Clinical trials in low-resource settings have unique challenges due to structural and 
financial inequities. To address this, understanding the setting and factors which influence the 
decisional process is necessary. This study investigates the experience of caregivers in a malaria 
vaccine clinical trial.  
 
Methods: We interviewed a total of 78 caregivers of pediatric participants previously enrolled in 
a phase II or III malaria vaccine clinical trial in Uganda, Tanzania and Kenya. Interviews were 
analysed using a framework analysis. 
 
Results: Caregivers of participants in this study made the decision to enroll their child based on 
economic, social and political realities which extended beyond the trial context and into the 
community and domestic context. The provision of health care was a dominant motivator for 
participation. Respondents reported social networks, rumours, hierarchal structures, financial 
constraints and family dynamics affected their experience with research. 
 
Conclusions: Caregiver choice was limited due to structural constraints. The decision to 
participate in research was embedded in community and domestic hierarchies. Future research 
should assess other contexts to determine how choice is affected in other low-resource settings 
when free medical care is offered.  
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Vaccines play a major role in public health and their development is dependent on clinical trial 
testing in human populations. Transnational clinical trials operate through collaborative 
partnerships that involve a wide array of stakeholders and participants from varying sociocultural 
backgrounds. Each of these stakeholders enter into clinical trial research with varying degrees of 
inequity linked to their role in the clinical trial and resource context (S. R Benatar, 2002; 
Emanuel et al., 2004). This inequity is of particular relevance for vaccine research operating in 
low-resource settings due to the discrepancy in resources between the trial centre and the 
research site in which it operates, which has implications for the choice to participate in research 
(Glickman et al., 2009).  
Phase II and phase III vaccine clinical trials establish the safety of a vaccine and determine its 
efficacy (WHO, 2017a). These trials involve large groups of participants who are living in the 
region where the disease targeted by the vaccine is endemic. Due to the operation of phase II and 
III trials in human communities, the social structures in the clinical trial site are highly relevant 
to the clinical trial design. To maximise the effectiveness of vaccines currently in clinical trial 
development, research needs to be sensitive to the social systems within the context in which 
they are operating (S. R Benatar, 2002; Emanuel et al., 2004). To gain a substantive 
understanding of the social system in the clinical trial site, communities must be engaged and 
voices of participants and their families heard (Glickman et al., 2009; Lavery, 2018; Loff, 
Jenkins, Ditmore, Overs, & Barbero, 2005; London, 2005; Pratt & de Vries, 2018). This 
engagement process provides insight into the decision-making structures around trial 
participation, communication needs and the interests of the community in the trial context.  
 
This study investigates the community context, communication needs, and decision-making 
processes of the caregivers of participants in a phase II and phase III paediatric malaria vaccine 
clinical trial (PMVT). Each of these trials operated in low-resource settings in multiple African 
countries. The phase II vaccine trial involved GMZ2 malaria vaccine and was conducted at five 
clinical trial centres in four African countries (Sirima et al., 2016). The phase III trial involved 
RTS,S malaria vaccine and was conducted at 11 clinical trial centres in seven countries (RTS,S 
Clinical Trials Partnership, 2015a). Operating across social systems, these transnational clinical 
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trials provide insight into the impact that vaccine clinical trials have on the local population 
while adhering to standardized clinical trial protocols. Local systems and cultures influence 
decision-making in clinical trial research and mapping the country-specific context supports 
successful transnational research for development (Hahn & Inhorn, 1999; Helman, 2007; Ward 
et al., 2017). This study takes these clinical trials as case studies to map the country-specific 
context and shed light on the caregiver and community experiences in clinical research in low-
resource settings.  
 
The phase III RTS,S clinical trial investigated here has led to the regulatory registration and the 
roll-out of the RTS,S vaccine in a phase IV study, making it the first licenced malaria vaccine. 
These phase IV studies will take place in three different countries, including the Kenyan research 
centres investigated here (WHO, 2018a). This makes the experiential understanding of the 
research participants, their caregivers, and communities in the context of the clinical trial centre 
even more pertinent.   
 
While community engagement has been recognized as necessary in ethical transnational 
research, there is no clear consensus as to its definitive application in different community 
contexts (Tindana et al., 2007). Context may influence the ways in which benefits and risks are 
perceived by the participants, particularly in settings with large resource inequities (Cottingham 
& Fisher, 2016; Walker, Cottingham, & Fisher, 2018).  Using knowledge of the health and social 
structures to inform community engagement practice is a critical component of designing 
research studies appropriately (Miller et al., 2010). Researchers conducting clinical trial studies 
in low-resource settings can integrate the findings of this study to protect participant autonomy 






In order to better understand the experiences and decision-making processes of caregivers during 
PMVT we conducted a series of in-depth interviews between March 2017 and March 2018 with 




Interviews were held across four different clinical trial sites in Uganda (Iganga), Kenya (Siaya 
and Kombewa) and Tanzania (Bagamoyo) with caregivers of participants. We used purposive 
sampling to recruit respondents and in the majority of the cases the mother was the primary 




RTS,S phase III malaria vaccine trial was carried out between March 2009 and January 2014 in 7 
African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, United Republic 
of Tanzania) and spanned across 11 clinical trial centres (RTS,S Clinical Trials Partnership, 
2015b).  
GMZ2 phase IIb malaria vaccine trial was carried out in April 2010 - July 2012 in 4 African 
countries (Burkina Faso (2), Ghana (1), Uganda (1), Gabon (1)) and spanned across 5 clinical 




This was a qualitative study that utilized in-depth interviews to capture the perspective of the 
caregiver who had a child enrolled in a PMVT. The field work consisted of a scoping trip to the 
research sites to introduce the study, recruit participants and meet with community leaders. The 
field visits took place in March 2017 (the scoping visit) and the interviews were conducted 
between May 2017 and March 2018 with the help of local research assistants. The research 
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assistants from Tanzania were fluent in Swahili (one female and one male). From Uganda all 
three female research assistants were fluent in Luganda and conversational in the related Lusoga 
language of the community investigated. In Kenya all three research assistants (1 male and 2 
female) were fluent in Dholuo. None of the research assistants lived in the community 
investigated, all were fluent in English and had post-secondary education. Interviews were semi-
structured and had a focused discussion on the vaccine trial, leaving room to explore concepts as 
they emerged, such as community dimensions and domestic relationships in the context of the 
trial. Funneling was applied, where interviews began by asking open questions and were then 
funneled into more specific questions about the respondent’s views and experiences within the 
health system, interaction with researchers, and challenges faced in the community. The 
interviews were recorded with the informed consent of the respondent and conducted in the local 
language. They were then transcribed verbatim and translated into English by the research 
assistant. The interview guide was first piloted in each country and then changed and developed 




The study protocol, informed consent forms, interview guide were reviewed and approved by the 
following bodies. In Tanzania: National Health Research Ethics Review Committee for the 
National Institute for Medical Council (NIMR); Ifakara Health Institute IRB (IHI-IRB); 
Tanzania Commission for Science and Technology (COSTECH). Uganda: Uganda Council for 
Science and Technology (UNCST); the Makerere University School of Biomedical Sciences 
Higher Degrees Research and Ethics Committee (SBS-HDREC). Kenya: Strathmore University 




The analysis was based on the approach described by Strauss and Corbin (1998) (Strauss & 
Corbin, 1998). First a detailed line-by-line microanalysis was conducted to identify categories in 
the data, this was followed by an exploration of the categories, their properties and the 
relationships between them. This was then discussed between the first author of this paper and 
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the local bilingual research team to ensure the accuracy of the analytical process. These 
categories were defined into main themes as illustrated in figure 1. These themes were then 
integrated into a framework to define the scope of the analysis and are presented in the results.  
 
Figure 1. Framework for analysis outlining the interplay between community, domestic and trial 





Of the 78 interviews a total of 23 were with parents of children enrolled in the GMZ2 Phase IIb 
trial in Iganga, Uganda. The remaining 55 in-depth interviews were with parents of children 
enrolled in the RTS,S phase III study across three sites in Bagamoyo, Tanzania (n=18), 
Kombewa, Kenya (n=20) and Siaya, Kenya (n=17). Interviews lasted around 31 minutes on 
average, with the longest being 56 minutes and the shortest being 19 minutes. Seven interviews 
could not be included in the time calculation due to logistical limitations of the recordings.  
 
The respondents made it explicit that they inhabit multifaceted realities falling under clinical 
trial, community and domestic contexts. Each of these themes is shaped and embedded in their 




Setting Dominant Themes 
Trial context 
 
• Social networks reported on high-quality care 
• Trial centre vs. government facility medical care 
• Social skills of trial doctors 





• Community valued health care 
• Reassured by friends about participation 
• Health benefits should be for the whole community 
• Trial improved conditions in the community 
• Local leadership influences community acceptance 




• Individual context leads to trial enrollment 
• Valued health care and improved condition of child 
• Fathers influenced enrollment, consent and withdrawal. 
• Explicit reality of sick child in the home 
• Outliers: Trial interfered with domestic harmony 
 
Table 1 Respondents reported their experience of the trial, community and domestic context. The 






Respondents frequently began by explaining their trial experiences and defined the role the trial 
played in their lives. They did not view the clinical trial as detached from their lives, instead 
participation was motivated by an array of political, social and economic factors unique to their 
lives.  
 
The mainstream opinion in this sample of respondents was a great appreciation that the trial 
provided free, high-quality medical care for their child during difficult economic conditions.  
R40: Before the research study, when you visit the government hospital after 
tests they were telling you to go buy medicines and sometimes you don’t have 
the money. But after my child joined the study the situation changed. I am 
grateful my child was getting malaria tests and given medicines in a sealed 
bottle not the opened ones. 
The contrast between the free medical care in the study and the options available to the parents 
through government hospitals was consistently highlighted by respondents.  
R56: We were comfortable because the health workers were approaching us 
well, they had good manners. At times you may go to the hospital and they tell 
you that you are stupid, but these ones were good health workers, they could tell 
you to do something and you accept because of their approach. 
 
The trial was also not independent from circulating rumors within social networks. Where the 
mainstream in this sample reported an appreciation for the trial and the medical benefits, a few 
outliers noted the impact rumors had on the way the study was perceived and pushed back 
against them. 
R34: Someone can spread rumors. We would tell them to go and see for 
themselves that there is nothing negative taking place. My child who is in the 
study is healthier than yours who is not but you keep talking about blood draws. 




The community played an integral role in the uptake, acceptability and integration of the clinical 
trial into the local setting. Caregiver decision making was intimately tied to their relationship 
with others in their local community. 
R46: Before joining I used to see my friends going and I guessed it would be a 
good project. When I joined, I was assured, yes, it was a good project based on 
their procedures and services given. 
A number of participants reported that the benefits of the trial should be available to everyone. 
Placing an emphasis on the need for the high standard of health care to be extended towards 
other members in the community.  
R32: Your neighbor ought to enjoy what you enjoy. The fruits you enjoy, he 
ought to enjoy. 
 
Respondents often reported from the perspective of the community and how the trial improved 
conditions for the children of their community as a whole, despite a lack of financial resources.  
R35: The people were enrolled praised the study. Most of them are the people 
who come from around who earn a little money. Sometimes when the child falls 
sick it becomes difficult especially for us who are farmers. They would give the 
children effective drugs. So, the people around consider it good. 
The local political leader has a significant influence on the trial. When the local leader is trusted 
by the community members and this individual approves of the trial, then the study participants 
will be much more comfortable.  
R64: Our chairman as you have seen him, he is good. Whenever the study 
people would leave, he could explain to us what was going on, so that’s how you 
could pick to participate. These ones who came straight to the chairman we 
knew that they are people of light, because we knew that someone who has not 
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come through the chairman is the one you can doubt but someone who has come 
through the chairman, there is no need to question. 
 
Where the mainstream in this sample reported satisfaction with the clinical trial, some outliers 
also reported cases where community members challenged the clinical trial and those enrolling 
their children.  
R65: Because at first the people were asking, why do you need our children? 
Which kind of check-up are you doing? What are you checking? As you know 




The caregivers of participants in the PMVT repeatedly spoke about the role that the trial played 
in their lives at home, in particular how the family’s access to medication influenced their 
participation.  
R14: My child she was very sick and when I went with her to the hospital I found 
the government sector had no drugs and the study did have drugs. So I went and 
found a sister and she asked me if I could agree to join the study, “if you agree 
to join then I will take you so that your child can be helped and if you refuse, 
you can go to other district hospital but even there are no drugs” So I sat with 
her and asked her and she had already told me that the study is very good. I 
asked her if they can help me and she said yes, only if I agree to join, and I said 
yes I have agreed to join and for sure they treated my child.  
 
Facing financial challenges within the domestic settings and then having the clinical trial provide 
free and high-quality care for the sick children was positive according to caregivers.  
R66: I benefitted because my child is still alive. 
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R35: My child would be given medication even when I didn’t have cash. They 
would also give me fare back home. It was good. Anytime I would take the child 
to the hospital, they would treat him.  
Fathers played a significant role in participation and many respondents who were mothers 
elucidated the role the father had in motivation and consent to join, or withdrawal from the study.  
R17: Others also took it seriously that those people are removing a lot of blood 
from the children. So they did not agree, and other people, including the fathers 
of the children never agreed which is why they didn’t join. 
 
Caregivers also explained what it means for them to have a sick child within the home, 
particularly how it could also lead to problems within the relationships. For the majority of 
participants this was improved when the children could participate in the study.  
R56: You need to eat yet the child is sick. You eat late because food is prepared 
late, you quarrel and can even fight. Such things happen and there is no love in 
the family because every time you are concentrating on the child. You may find 
that even some men get other women, complaining that they are fed up of the 
other one because her children are sickly.  
While the mainstream opinion in this qualitative sample expressed appreciation of the trial and 
the way in which it benefited the families, in some exceptional cases participation in the trial 
could lead to problems in the spousal relationship.  
R78: They were removing a lot of blood. Maybe they just needed a lot. I was 
afraid that he will collapse and his father will beat me up. I was afraid but there 






The findings of our qualitative in-depth interviews with caregiver of participants enrolled in a 
PMVT provide insight into the values that caregiver hold, what motivates their participation, and 
their experience in the clinical trial. The primary motivation for participation drew from each 
theme (trial context, community context, domestic context) and is intricately connected to the 
political, social and economic reality that a caregiver occupies at a given time. Below we move 
through these themes and discuss the role local values and beliefs play in research participation. 
 
What is most striking about our results is the dominance of free medical care as being the 
prevailing motivator for participation. Limited capacity of local medical services has been raised 
as a challenge in transnational research when the medical services in the clinical trial 
significantly surpass local services (Mtove et al., 2018; H. T. Shapiro & Meslin, 2001). It is 
cross-cutting across all themes analysed in our study and is repeatedly emphasised by caregiver 
of participants enrolled in the clinical trial as being the most valued and positive component of 
the research trial. This finding illustrates the interplay between the local structural limitations and 
trial enrollment, having significant implications for individual decision-making processes 
concerning the trial (Chuan & Schaefer, 2015; Paré Toe et al., 2013). Having a powerful 
motivating factor, such as the provision of care in this context, prevalent across all themes is 
indicative of local structural constraints. The provision of care to participants in clinical trial 
research is presented as ‘benefit-sharing’ where the clinical trial aims to give back to 
participants. This ‘benefit-sharing’ with individual participants in a setting where the institutional 
health care structures are limited may impede choice with regards to enrolment (Hayden, 2007). 
Failing to balance the provision of care with concise communication around trial proceedings to 
the caregiver can lead to an ‘empty choice’ where structural factors around health care eliminate 
an autonomous decision (J. A. Fisher, 2013; Kingori, 2015). A caregiver of a participant will be 
limited in their autonomy when faced with the decision to enroll when it is their only means to 
ensure their child’s health. This is relevant for both informed consent, but also risk versus benefit 
communication in transnational clinical trials (J. A. Fisher, 2013; Molyneux, Peshu, & Marsh, 
2005; Mtove et al., 2018).  
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Beyond the individual, the provision of accessible medical care was also highlighted as the trial 
component most highly valued by the community. Health care was framed as a community value 
by respondents. The political leadership which influenced community acceptance of the research 
suggest a locus of decision making that is communal. The leadership in the community decided 
its position on the research study and then passed this approval down into the community, driven 
by the desire to promote the health of the children. The provision of health care within the 
community context in combination with the structural constraints, impact decision-making 
structures in clinical trials and provide challenges for the consent process (Fitzgerald, Marotte, 
Verdier, Johnson, & Pape, 2002). Communal decision making extends beyond traditional liberal 
political philosophical notions of autonomy and informed consent, this contextual reality was 
described by one caregiver as “the village life we are in”. The respondents are embedded in 
communal lives where other members of the community would suggest their child was going to 
be killed or face the consequence of a stigmatized condition if they enrolled in the PMVT. 
Failing to recognize the contingency of community and individuality and to overlook the 
historical experiences that contributed to the generation of these beliefs can derail research 
studies (Kingori, Muchimba, Sikateyo, Amadi, & Kelly, 2010). Our results, in combination with 
the contingent notion of community in informed consent processes, place an emphasis on the 
need to clearly communicate risks and benefits to the trial community so that they are not 
overshadowed by the benefit associated with health care provision.  
 
The final analysis of the domestic context also brought the value of health care provision to the 
forefront as the dominating motivator for trial participation. Having a sick child in the home 
leads to difficulties for others sharing that same domestic setting, whereas having access to 
health care to treat the sick child leads to greater domestic harmony. Respondents reported that 
enrolling in the research trial often occurred as a result of the difficulty in accessing medical care 
and trial enrollment has been reported to be lower in areas with better medical services (H. R. 
Fisher, McKevitt, & Boaz, 2011). This illustrates the power that the provision of medical care 
has when it is embedded in a low-resource context, distorting a balanced risk and benefit analysis 
or leading to the negation of the risks all together. 
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How parents weigh the risks and benefits of participation differed and was related to the 
structural constraints around health care access for the child (Kingori, 2015). Health care 
provided by the PMVT was reported to be highly valued by both parents and improved the 
condition of the child. This trickled down into having effects on the relationship the mother had 
with the father as well as the overall “joy” in the home. Having a sick child in the home can 
burden the relationship and make parents more likely to participate in research than when their 
child is healthy (H. R. Fisher et al., 2011).  Individuals living in contexts with few medical 
services will see medical provision as a much larger benefit to their family than those in contexts 
with a strong local health system, calling for a tailored communication approach appropriate for 
each setting.  
 
The absence of risk in the interviews conducted was also of note. Sceptical beliefs or concerns 
were often framed as “rumours” by respondents and those believing them were referred to as a 
distant third party. Respondents repeatedly emphasized the gratitude they experienced from trial 
enrolment and the accompanying care. Concerns around potential adverse events outlined in the 
informed consent documents associated with vaccination did not come up as a significant 
concern during the interviews. While therapeutic misconception was also evident in some 
interviews, the offer of medical care over-shadowed it in its ability to influence the caregiver’s 




Designing vaccine clinical trials in low-resource settings such that the communication of risk and 
benefits is done in a way that is comprehended by participants and their communities is a 
challenging task. Ethical design of research requires the communication of trial proceedings not 
to be overshadowed by the provision of free care in resource-limited settings. To address this in 
future trials and taking the first step towards more ethical communication means placing the 
community at the forefront of research design (D. E. Beauchamp, 1985; Callahan, 2003; V. M. 
Marsh, Kamuya, Parker, & Molyneux, 2011). Putting the community central to the research 
means to understand the values present in the settings where the research is taking place and how 
these are situated relative to the individual and their decision-making processes. This can be 
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achieved through stronger engagement with local stakeholders and health systems, including 
strengthening the government health system (Ward, Shaw, Anane-Sarpong, et al., 2018). The 
second step is to design clinical trials in collaborative partnership with local leadership to foster 
local capacity building and ultimately strengthen local health capacities (Ward, Shaw, Sprumont, 
et al., 2018). Being responsive to community needs and integrating values that influence 
participation in research alongside local leadership can provide a more balanced conception of 
the risks and benefits. The active involvement of both community and local leadership can 
support the disentanglement of comprehension barriers while still allowing for ‘benefit-sharing’. 
An iterative process executed by the clinical trial team that engages the community and works 
closely with local leadership will foster research communication and thereby participant choice.    
 
Understanding and addressing the local context will reduce inequalities inherent in transnational 
clinical trials in low-resource settings (Launiala & Kulmala, 2006). The utilization of this 
understanding and its translation into research will support the communication of research 
appropriate for the local setting (Mwenesi, 2005; Williams & Jones, 2004). This involves 
integrating the social, political and economic components into clinical trial design and paving the 
way towards more equitable research practices and infrastructure that enables a real choice for 
study enrollment.  
 
Limitations of this study include the sampling strategy, which recruited caregivers who enrolled 
their child and therefore would have been more likely to have a reduced risk perception due to 
the provision of care than caregivers who were approached and refused to enroll their child in the 
clinical trial. Future work investigating the perception of caregivers in the community who 
refused to enroll their child could shed further light on this topic. We also did not interview and 
male caregivers, which is indicative of the traditional caregiving roles where the mother or 
grandmother has the primary responsibility for the child’s health.  
 
Through mapping how contextual realities interplay with the decision-making process of 
caregivers of pediatric clinical trial participants, this study can strengthen clinical trials in low-
resource settings. Our work shows that individual consent in clinical trials is intricately linked 
with community consent and family dynamics. Based on this, future research needs to 
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investigate how this interplay varies across contexts and the role free medical care plays in 
consent in these settings.    
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Background: When a vaccine clinical trial enters a human community two independent systems 
merge into one system with various levels if interdependence. This system exhibits non-linearity 
and unpredictability, creating challenges for the research team. In this study we explore the 
researcher experience during clinical trials in human communities, through the lens of complexity 
theory.   
 
Methods: We conducted in-depth interviews with a total of 11 researchers working on a phase III 
vaccine clinical trial in Kenya (Registry name: RTS,S ClinicalTrials.gov; Registry number: 
NCT00866619; Registry date: March 20, 2009). The interviews captured the researcher’s 
experience of working in a complex adaptive system and were analysed using thematic coding.  
 
Results: Both human communities and clinical trials have the attributes characteristic of complex 
adaptive systems. Challenges researchers encountered working in this merged system include 
rumours, suspicion related to blood draws, and misconceptions. The researchers highlighted that a 
foundation of trust and open communication were foundational blocks to embrace the non-linearity 
of the system.   
 
Conclusions: We have identified the key role that complexity theory plays in improving clinical 
trial design. The factors identified by our respondents, as seen through the lens of complexity 
theory, are integral to informing how clinical trial research can be tailored to the local social 
setting. Understanding the system (community and trial) as one allowed for the identification of 
patterns that influence the emergence of the system. This calls for clinical trial design to 
incorporate iterative practices to better equip research teams to adapt to the emerging behaviour of 





Clinical trials are a critical part of the vaccine development process to establish both the safety and 
effectiveness of a vaccine. Vaccine clinical trials have extensive regulatory requirements and 
operational components to adhere to (WHO, 2017a). These clinical trials take place in human 
communities where elaborate social networks and environmental factors form the community. 
When research such as vaccine clinical trials enter into a community, a complex array of 
considerations come into play and affect the outcome of the research. Considerations specifically 
relevant to the social complexity of the community and the regulatory complexity of the clinical 
trial.  
There are particular considerations specific to clinical trials being conducted in low-resource 
settings. The majority of vaccines currently in the development pipeline target diseases endemic 
to populations living in these settings (WHO, 2019). These considerations are unique due to the 
large resource discrepancy, with a high-capital vaccine clinical trial centre conducting research in 
a low-capital clinical trial site within which the communities are located. This has significant 
implications for communication, benefit-sharing and engagement with the community (van den 
Berg et al., 2019a). To explore these implications, we take the unique approach of utilizing 
complexity theory to explore the unfolding of a new complex adaptive system (CAS) when a 
clinical trial conducts research in a community (Gilchrist, 2000; Mathews, White, & Long, 1999; 
Neely, 2015; Ramalingam, Jones, & Overseas Development Institute (London, 2008). 
Here we investigate the experience of two vaccine clinical trial research teams working in 
communities in Kenya. We have selected a phase III clinical trial of the leading malaria vaccine, 
RTS,S, to study the interplay of the research team with the community. This multinational, phase 
III study was carried out across seven countries/systems and cultures with rigorous, standardized 
regularity requirements in all eleven trial centres (RTS,S Clinical Trials Partnership, 2015b). These 
regularity demands on research teams occur in vastly different contexts. With a focus on Kenya, 
we look through the lens of the researchers working in the community during the phase III malaria 
vaccine clinical trial. In 2019, this vaccine will be rolled out in phase IV studies in three different 
African countries (WHO, 2018a). This vaccine clinical trial is therefore characteristic of large, 
multinational clinical trials operating in a low-resource setting. This clinical trial team has proven 
to effectively work with the community such that the research will continue into a phase IV study. 
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Through this evaluation we shall better understand the factors at play when a complex clinical trial 
system enters a complex social system. 
Complexity theory is a useful framework for vaccine clinical trials operating in low-resource 
settings. Communities and clinical trials are CAS (Gilchrist, 2000; Mathews et al., 1999; Neely, 
2015; Ramalingam et al., 2008). The conduct of vaccine trials merge two CAS, the clinical trial 
and the community, into a new system. In essence, CAS describe systems that have components 
of non-linearity, iteration, unpredictability, interdependence and emergence (Holland, 2014; 
Maguire, McKelvey, Mirabeau, & Oztas, 2006; Sawyer, 2005). Cilliers (1998) outlines a CAS as 
a system with a history that impacts the current state and its evolution, a system that has many 
concurrent interactions which are characterized by feedback loops and is open to the external 
environment (Cilliers & Spurrett, 1998). Based on these attributes, the merging of a complex trial 
system and a complex social system requires prospective considerations for researchers working 
in vaccine development. To better understand these considerations and their consequences, the 
experience of researchers in this phase III malaria vaccine clinical trial in Kenya is evaluated. This 





In order to capture the researcher’s experience in the community during a vaccine clinical trial in 
a low-resource setting, we conducted a series of in-depth qualitative interviews in March 2018 
with members of the RTS,S phase III clinical trial. This study was part of a larger project looking 
at clinical trial research in low-resource settings and the methodology presented here relates to 
other work (van den Berg et al., 2019a).  
 
Study Design 
The phase III transnational clinical trial was carried out between March 2009 and January 2014 
covering eleven clinical trial sites in seven African countries (Burkina Faso, Gabon, Ghana, Kenya, 
Malawi, Mozambique, United Republic of Tanzania). Upon the completion of the trial, post-trial 
epidemiological monitoring has continued to be done. All respondents were based in Kenya. 
 
In-depth interviews 
Interviewees were asked about their role as a researcher in the clinical trial, particularly their role 
in community engagement, focusing on relational dynamics and communication in relation to the 
formation of a CAS with the trial team and the community. Questions were also focused on 
identifying their personal perception of the community, both positive and negative, and the ways 
in which they responded to those experiences.  
Purposive sampling was used, all respondents were researchers involved in the RTS,S malaria 
vaccine candidate phase III or post-study epidemiological monitoring (ClinicalTrials.gov 
Identifier NCT00866619). Trust was established by visiting the centre in March 2017 and 
introducing the study and its aims, maintaining regular contact and then returning to the clinical 
trial centre in March 2018 to conduct the interviews. The interviews were conducted by the first 





Interviews were recorded, transcribed and then coded using MAXQDA software. Transcription 
began immediately after data collection and inductive detailed line-by-line microanalysis was 
utilized to identify categories in the data. Based on these categories, relationships were identified 
and organized into themes. All interviews were conducted, transcribed and analysed by the first 
author and parts of the coding were reviewed by the co-author SM. The focus of the analysis was 
on researcher values, lived experience and views on community engagement to best identify the 
CAS from the researcher’s experience. 
 
Ethics 
Ethical approval was obtained from the Strathmore University IRB (SU-IRB) in Kenya and written 
informed consent was obtained from all respondents for the in-depth interviews. All data was 






The results presented here relate to earlier work looking at the experience of caregivers of pediatric 
participants in malaria vaccine clinical trials (van den Berg et al., 2019a).  
Eleven interviews were conducted with members of the research team. Respondents had various 
roles in the research team but all were involved with the RTS,S malaria vaccine clinical trial. The 
average length of an interview was 53 minutes, with the shortest being 28 minutes and the longest 
2 hours.  
In the interviews, respondents described their experience in the community and overall 
impressions with great detail. Respondents described communities as dynamic and outlined the 
experiences they had when working in community systems. In particular, challenges associated 
with blood draws, rumours and misconceptions arose, as well as the ways in which they dealt with 
these. Often a foundation of trust and continuous communication were reported to be key for 
clinical trials to work in a community and through complexity theory this foundation can be used 
to embrace the non-linearity of the system and effectively work in it. Below we present the 
alignment with these descriptions and CAS, as well as the indicators that when a clinical trial is 
initiated in a community they merge, and they exhibit interconnectedness and interdependence and 
behave as one cohesive system. 
 
Communities are complex adaptive systems 
The ways in which respondents defined community was strongly aligned with attributes related to 
unpredictability, non-linearity and emergence associated with complex adaptive systems. When 
discussing work in the communities, respondents described a dependency on a complex array of 
factors. Throughout the interviews, researchers brought up their definitions of community from 
their perspective, in particular the diversity across various communities and the ways in which this 
impacted the trial. 
P11 Working with communities is dynamic. There are pros and cons about 
working with communities. But it depends on how you conduct yourself in the 
community and how you engage the community.  
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P10 It depends on the social make-up of the area where you are. For example, we 
had more withdrawals from the central area than from the more rural outlying 
clinics.  
 
Challenges of working in CAS 
The impact of misconceptions around adverse events and risks was reported by all respondents, 
which could vary depending on the community context. These misconceptions arose out of 
contextual factors within the community system, as there are multiple factors acting on the 
community simultaneously to the trial procedures. These also indicate the merging of two 
independent systems (trial and community) displaying significant interdependence. The challenge 
in dealing with this was also raised, particularly in sensitive cases when a participant has died from 
causes not related to the vaccine study. Here the community blames the powerful clinical trial for 
an event where helplessness is experienced in the community, indicative of a power imbalance and 
linked to the hierarchy characteristic of CAS. The non-linearity and complexity of working in CAS 
settings was evident, as well as the experience for the researcher being a part of the community 
system and then having to return to an unpredictable scenario.  
P08: If for example after a participant dies, it becomes another challenge 
altogether because a participant can die from another cause. But then people 
sometimes feel that in a way you contributed to that. But you see those who are 
participating at least they know because they went through the whole treatment 
procedure and everything so then they understand. But now the whole community, 
even when you are going to visit these compounds you feel when you are going 
you are not really sure of what can take place, because you are going, and you 
don’t know if maybe some people will turn wild and attack you or something. But 
then it never happened, really, actually, it never happened. 
The interviews revealed consistently that there are many concerns from the community with 
regards to blood draws and transfusions, illustrating that communities are not operating in 
isolation, instead they are imbedded in contextual histories where clinical trials were, at times, 
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exploitative. This overlapped with religious motives for denying medical intervention such as 
blood transfusion or oxygen for a sick child enrolled in the clinical trial. Many of the communities 
have rooted beliefs around blood, arising out of these historical research experiences.  
P08: The main issue in the community is about blood samples that we take, that 
one is a major issue. People want to know “what are you doing with the blood?”  
There are multiple factors that play into the consent process and it is rarely the person who consents 
(frequently the mother) who has the only say in the child’s participation. The concerns around 
blood or other misconceptions are often heightened in those family or community members who 
haven’t gone through the formal consent process. Different communities have varying 
employment realities, which contributes to the social make-up and transience of fathers at a given 
moment in time. This is not predictable and adds a layer of complexity to operating in a 
community. 
P02: Some homes you had the father, or the head of the household, who does not 
want anything to do with vaccine research because of the perspectives. So they 
would be hostile. And threatened, “leave my home, I don’t want my children in 
those studies, you’re taking blood for what? You’re making money with our 
blood!” 
In a few cases it was highlighted that external research projects being conducted in the area 
interfered with the perception of the research study. In particular, it was noted how some 
researchers bypassed community engagement processes. As the community did not necessary 
distinguish between research institutions due to the overlap of activities, this generated further 
broad suspicion around medical research.  
P11: University students that don’t know how to do it and they’re in a hurry to 
get their data. They just say, take these 200 shillings, I want to remove the blood 
of the child. And the community kept on thinking it was us. 
It was widely reported that having local staff was necessary for effective community engagement 
and necessary for an understanding by the trial team of the sociocultural norms and economic 
contexts unique to the participants. However, it was also acknowledged that in the event of an 
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employment termination there could be a disruptive impact on the community-trial relationship. 
These explicit demands by the community for more reciprocity from the clinical trial was 
indicative of the community’s experience with the power imbalance. The economic and power 
inequity was seen as a particularly delicate issue for the research team, in line with the hierarchal 
nature of CAS.  
P02: There are instances where the family would say “My daughter was looking 
for a job but you never hire people here from this community, you want to bring 
people from outside to come and work for you” so probably a percentage of your 
field team should come from the community, because now the community relates, 
they know these people, these people live amongst them, there is no way they can 
bring something bad to them. 
P02: We have a family around the community, one of their children was hired 
here but because of negligence, he used to miss, he lost his job. So the family was 
mad at the organization so they would go around the community and discourage 
people from engaging with us.  
How researchers work in complex adaptive systems 
It was cross-cutting across respondents how important it was to understand the people in the 
community, show concern and express gratitude for their participation. This was an important 
aspect to working harmoniously in the community through strengthening the communication and 
comprehension. At times, the researchers identified the power imbalance within the CAS between 
the clinical trial and the community, feeling that more needed to be done for the community and 
the participants.  
P02: Think about their needs and don’t treat them as a subject, treat them as 
someone who has sacrificed their time who has put aside some of the things they 
were supposed to do to come to the clinic. 
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P07: You get to learn their challenges, or their fears, or their reservations. And 
then you get to explain why you are doing what you are doing at that time point 
and why you are planning to do it or why you are not planning to do it.  
Understanding the role of community leaders, especially elected leaders, attributed to positive 
opinion of the trial within the community – as they can have a major impact in the community and 
determine the directionality of the engagement. It requires careful engagement by the research 
team, as it is necessary for the success of the trial to have the chief’s support.   
P05: And the chiefs, those ones you must have on your side, before you try 
anything. Because if they decide you treated them disrespectfully that study is not 
going onwards, they’ll say don’t enroll, they’re doing this, maybe they’re selling 
blood. 
Being aware of the norms and subsequently approaching misperceptions in accordance with those 
norms was reported as being a continual iterative learning process. For instance, addressing power 
dimensions and sending the appropriate staff member to provide clarification in challenging 
situations. A few respondents clearly identified how important it is to have members of research 
team that are culturally versed and sensitive to local norms. Without this there can be implications 
on perception of the study, without the researcher themselves being aware of it.  
P05: He is familiar what not to do. Maybe when you enter a household, how you 
should enter, who you must see before you start seeing. You can’t just enter a 
homestead and just start talking to anyone you want, it’s inappropriate. 
Frequently it was reported that staff should not only be properly trained, but also selected based 
on their fit within the community norms. This was seen as key to maintaining a trusting and strong 
relationship with community members.  
P11: You must know who your staff are. Others are outgoing, others are 
introverts. You can’t send an introvert to the village, they will be closed. The 
villagers will not share with them.  
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Respondents often brought up the role that trust plays in communicating with the community and 
maintaining harmony. The ways in which this was built was through consistent and transparent 
communication, as well as adhering to the proposed study protocol without surprising the 
community with new procedures.  
P09: Trust is in the core of the understanding between the staff and the 
community. 
Hosting information sessions that are inclusive to all members of the community (not only those 
who consent and the participants) was reported to be a positive contribution to the trial perception 
and addressing information gaps. It is helpful to have regular sessions where all can attend and 
have access to information updates to avoid a powerful voice having a misconception or 
information gap.  
P11: Communicate and talk to them at every level. Right from the time they come 
to the clinic. To not be tired of communicating, communicate all the time. 
Informing the community about research findings was also highlighted by the respondents. 
Especially in the long-term view of the research study and supporting future recruitment was 
identified to be tied closely to ongoing engagement and keeping the community informed.  
P01: I think people want to know where you have reached, because especially if 
it is not a perfect vaccine, for the lack of another word, then people will need to 
come back again, provided that the disease remains a problem, to come back 
again to the community. That’s a major challenge, especially for large studies.  
The introduction of a new research project, in this case a new vaccine, required a lot of clarification 
and engagement. Especially ongoing involvement of the community to raise understanding and 
comfort with the new tool. The nature of this involvement was dependent on the community the 
research team was working in.  
P08: What I have learned in this community, is that if there is a vaccine that is 
injected, a lot of mobilization needs to be done. Because you find that in these 
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areas there are not many vaccine trials that previously had been done so people 
don’t really know how the vaccine trial is done, especially one that is injected.  
The establishment of the Community Advisory Board (CAB) was reported to be beneficial as a 
tool for staying aware of the community developments. Having regular meetings allowed the 
clinical trial team to address misconceptions and information gaps, as well as adapt appropriately 
to new situations.  
P01: I would not start a study without telling the CAB, it would almost be suicide. 
If something goes wrong, even if you don’t know who to tell, you see then you 
have already told them “oh remember the study, we discussed, oh this is what is 
happening” or they already know about it, so if they hear a rumour they can tell 
the people, we heard, but that is not really it.  
A number of respondents identified the need to translate informed consent forms into contextually-
sensitive language. It was reported that certain words translate poorly into the local language, with 
the consequence of creating community suspicion towards the researchers.  
P04: Allowing the use of more latitude with how we translate, meaning it should 
not be word-for-word, which is what they tend to look at, but it should be more 
context.  
Despite the various ways in which challenges were addressed and the overall benefits attributed to 
the clinical trial working in the community, a few respondents called for more to be done. These 
researchers felt that with the power of the clinical trial and the benefits received, the community 
needed to benefit more and the trial needed to do more in return and acknowledge this power 
discrepancy.  
P02: Being an organization working in a community, you should give back to that 
community. You should show concern, don’t just collect data and forget about 
them. 
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P07: Different communities have different expectations, it is really challenging 
because when we are starting the trial the new satellite facilities were looking 





Clinical trials carried out in and merging with communities exhibit many attributes of complex 
adaptive systems including historical influence, dynamic interactions, nonlinearity and 
interdependency (Cilliers & Spurrett, 1998; Helbing, 2013). A useful definition by Neely (2015) 
describes a complex adaptive system as a system in which agents are interconnected and 
interdependent and their individual actions form patterns of repetition that create emergent 
structures which have a non-linear influence on agent behaviour and further emergence (Neely, 
2015). Drawing on this definition, the initial state includes an independent community system and 
an independent trial system, each governed by an independent set of rules. Upon the initiation of 
the clinical trial in the research site, these systems merge and their components exhibit 
interconnectedness and interdependence. This leads to the generation of an entirely new CAS with 
a non-linear influence on system behaviour and emergence, open to the external environment. 
Through approaching clinical trial conduct in low-resource settings with the utilization of CAS, 
additional insight is provided through enabling the design to view the system holistically and equip 
researchers with tools that enables them to embrace the non-linearity and adapt effectively. 
Specifically, understanding clinical trials in this way allows for the identification of patterns that 
influence the emergence of the system and subsequently ways to address traditional components 
of research considered outside of research team control.  
The community system has social networks, trial information sessions, family dynamics, 
employment, rumours, and a health system that lead to continual evolution of the CAS (van den 
Berg et al., 2019a, p.). The trial system is operating within its own set of rules guided by sponsors, 
eligibility criteria, trial protocols, participants, Good Clinical Practice (GCP) guidelines, and 
payment terms. These two systems are also open, and thereby constantly in exchange with the 
external physical environment that carries with it influences from media, scientific progress, 
research studies, disease, ethics committees, and routine vaccination programs (figure 1). Between 
the community and trial, a significant power discrepancy is present, indicating which actors have 
a greater influence on CAS emergence. Each of these aspects was touched upon during the 
interviews and support CAS theory as a useful model for vaccine clinical trial research in low-
resource settings. Therefore, approaching community relations during clinical trials in low-
resource settings with implicit linear and mechanistic assumptions will see inconsistent outcomes. 
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In contrast, we have found that clinical trials within communities is a deeply iterative process, 
dependent on feedback loops and the interaction of dynamic networks.  
 
 
Figure 1. Complexity theory modeling a community system (red), clinical trial system (blue) and 
the external environment (green) merging into a new iterative system. The identified factors 
operate within feedback loops and demonstrate an interconnectedness with each actor. The solid 
arrow indicates the directional weight of power in the system, which is significantly greater on the 
side of the clinical trial.  
 
In this study the phase III malaria vaccine clinical trial was used as a case study to understand the 
consequences of two CAS merging and the prospective considerations of relevance for research 
teams working within this newly merged CAS. Figure 1 models the identified actors and the factors 
at play in shaping the behaviour of the system. Currently, clinical trials are designed with the 
assumption that the clinical trial system and the community system operate in isolation. However, 
the findings of our case study indicate that the emerging behaviour of the system contradicts this 
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assumption. Therefore, denying the interconnectedness of the community and trial is detrimental 
to the success of the trial as it does not allow teams to adapt to unpredictable system behaviour. 
We found that challenges concerning rumours, community scepticism of a new vaccine, 
employing community members, minor events with unforeseen consequences and hierarchal 
structures are all behavioural indicators of one interconnected CAS. This CAS operatives with 
cyclical iterative feedback loops (figure 1) and requires researchers to respond in a similar iterative 
manner to these challenges. For the research team in this case study, a certain amount of iteration 
occurred informally and was needed for the trial to proceed in response to these challenges. Below 
we describe the emerging behavior of the system upon the merging of a clinical trial with a 
community. In particular the challenges identified by the researchers when carrying out a 
transnational clinical trial, adhering to standardized clinical trial regulations, while attempting to 
adapt to the non-linearity of the new system.  
 
One of the main challenges reported by researchers is the difficulty in addressing misconceptions 
and preventing the spread of rumours, a concern frequently described in clinical trial research (P. 
W. Geissler & Pool, 2006; Kingori et al., 2010). Our respondents identified community concerns 
that highlighted commonly reported suspicions around blood, infertility and death in relation to 
the clinical trial (Fairhead, Leach, & Small, 2006; P. W. Geissler & Pool, 2006; P. Wenzel Geissler, 
2005; Kingori et al., 2010; Mitchell, Nakamanya, Kamali, & Whitworth, 2002). As this is 
commonly reported during clinical trial research in low-resource settings, it is worthy of greater 
attention during clinical trial design (van den Berg et al., 2019a). Contextual and historical realities 
influence these rumours and simply providing access to the correct information alone is not 
sufficient to eliminate them - as they are shaped by the history of community system (P. W. 
Geissler & Pool, 2006; Obrist et al., 2007). The concatenation of historical events affect CAS and 
the way in which external factors integrate into the open and dynamic system (Gilchrist, 2000; 
Luhmann, 1995). Our respondents reported the interplay of social history with clinical trial 
outcomes and future trust in research, showing that it is insufficient to assume independence of the 
social system from the clinical trial system.  
 
 79 
To adequately address rumours, or better to prevent them, clinical trial design needs to 
acknowledge the emerging CAS that occurs when researchers enter a community. This extends 
beyond the initial introduction of the study and into the feedback sessions following the conclusion 
of the research. This will impact both clinical trial outcomes and future trust in research as rumours 
can be a reflection of the community’s sense of dependence and inequality in relation to the clinical 
trial, expressed in familiar ways to the community (Enria et al., 2016; P. W. Geissler & Pool, 2006; 
van den Berg et al., 2019a). A few respondents in our study expressed an awareness of this 
dependence and inequality. Highlighting the need for more to be done for the communities in 
which they are working, “you cannot just collect data and forget about them”.  
 
The kaleidoscope of feedback loops that are a part of the dynamic interactions within the CAS can 
make the identification of rumours and their roots difficult, however acknowledging this 
complexity and its consequences is necessary to strengthen clinical trial design. This can begin by 
identifying the rules which govern feedback loops related to rumours and to the historical roots 
out of which they have arisen. This can then be utilized for stronger community relations through 
communication about the vaccine by targeting these aspects specifically as a research team within 
the CAS (Essé et al., 2008; Ojakaa et al., 2011).  
 
Beyond historical events which influence the CAS, introducing new and unfamiliar components 
into a system can also create unpredictable and non-linear outputs in the system. Within CAS, the 
outcome of an intervention can be major with what seems like a small situational change (Cilliers 
& Spurrett, 1998; Maguire et al., 2006). Researchers reported the challenge of introducing a new 
injectable vaccine study into the community, particularly when it is the first clinical trial taking 
place of this magnitude.  
 
The inherent quality of CAS is unpredictability, in part due to the numerous feedback loops and 
networks interacting. For instance, the sensitization process around introducing a new vaccine 
could be further complicated by the presence of external research institutions conducting different 
studies, as was reported by respondents. The clinical trial is embedded in the social system but 
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also open to the external environment. These external factors have an influence the CAS and aligns 
with three attributes that Cilliers (1998) assigns to CAS: i) complex systems are open systems, ii) 
complex systems consist of a large number of elements iii) these elements interact dynamically 
(Cilliers & Spurrett, 1998). These attributes are also evident in the concerns raised about the 
introduction of a new HIV vaccine, where they highlight the importance of well-trained staff and 
a sensitivity to the local variations in vaccination culture (Streefland, 2003a). Other qualitative 
work in Kenya has also called for a greater emphasis to be placed on the norm sensitivity of health 
workers providing vaccine, as this is a way of identifying the rules of the CAS and thereby 
addressing the concerns as there emerge (Ojakaa et al., 2011).  
 
While CAS outcomes are non-linear and dynamic, patterns of interconnections and cultural 
concepts emerge in each community, which impact the acceptance of a new vaccine (Schaetti et 
al., 2011; Streefland, 2003a). Work looking at introducing a new human immunodeficiency virus 
(HIV) vaccine also emphasizes the importance that staff is prepared to adapt to new contextual 
settings (Streefland, 2003a).  Respondents often spoke about the role of local staff who were well-
versed in cultural norms as well as the importance that the rest of the research team is aware of the 
community sociocultural values. Being embedded in the community and viewing it through the 
lens of complexity theory enables clinical trial researchers to better understand the rules governing 
the cause and effect within the local context (Sawyer, 2003). However, operating in this way within 
the community is not without challenges (Chantler et al., 2013). The dispute that respondents 
described of a staff member losing their employment and subsequently contributing to circulating 
rumours or a politician using social events to gain support through discrediting the trial can be the 
consequences of being embedded in the communities in this way. The balancing of the clinical 
trial domain and everyday community life is challenging and requires a careful mediation that is 
open and searching (Chantler et al., 2013; P. Wenzel Geissler et al., 2008). Within complexity 
theory, these reported events are known as the butterfly effect where small changes in the initial 
system have major emerging implications (Capra, Juarrero, Pedro, & Uden, 2009; Holland, 2014). 
The simple act of a community member losing their job due to not meeting the requirements, had 
implications on the trial as a whole and resulted in the spread of rumours that impacted the 
emerging image of the trial – an unpredictable, minor event that created ripples in the larger system 
as a whole.  
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The unpredictability and non-linear nature of CAS described above makes clinical trial research 
in low-resource settings challenging. The social system in which the research is carried out must 
therefore be integrated into the study design and not simply viewed as a single element of the 
clinical trial system. In addition to being aware of the cultural values and norms which influence 
the rules of the CAS, the hierarchy of the system is relevant to these rules as well. CAS are systems 
that have a hierarchy of power (Gilchrist, 2000). Central to the mediation within communities are 
the leaders, having a strong influence on the system as a whole. Respondents reported them 
contributing to the overall acceptance of the trial and also as having the power to create suspicions 
around blood draws if these hierarchal structures are not respected. Community leaders in Kenya 
have been identified to use their authoritative power to promote clinical trial acceptance or generate 
suspicion, depending on their perception of the research team (Angwenyi et al., 2014). Being 
aware of this hierarchy within the community will support researchers by equipping them with the 
ability to better understand the rules governing the feedback loops and networks within the 
community and the emerging patterns. 
 
By integrating the above learnings into community engagement practises, vaccine clinical trial 
design can better embrace the unpredictability inherent to research in human communities. As the 
merging of a clinical trial and the community form a CAS, researchers working in any clinical trial 
that is embedded in a human community need to have the tools to be dynamic and adaptive to local 
realities. Designing a clinical trial with components of iteration and reflexivity in synergy with the 
regulatory requirements will equip researchers to better adapt to the emerging behaviour that is 
inherent to all social clinical trial systems.  
 
CONCLUSION 
In this study we have identified the behaviour of a clinical trial system upon the merging with a 
human community. The factors identified by our respondents, as seen through the lens of 
complexity theory, are integral to informing how clinical trial research can be tailored to the 
local social setting. This expands into all clinical trial research operating in human communities. 
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Prospectively, this pushes clinical trial design to incorporate iterative practices that adapt to the 
feedback loops and emerging behaviour of the clinical trial.  
 
Here we have identified the key role that complexity theory plays in improving clinical trial 
design. Further research investigating other clinical trials and geographical settings through the 
lens of complexity theory is needed. This can build a consensus on specific system behavioural 
patterns that most heavily require an iterative focus by the clinical trial team. Through the 
establishment of these patterns a more standardized approach can be used to design iterative 
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When clinical trials enter human communities, two complex systems merge – creating 
challenges for the clinical trial team and the human community. This is of particular relevance 
for clinical trials in low-resource settings where the resource scarcity can intensify inherent 
inequities. Complexity theory is a useful lens to better understand and design clinical trials to 
reduce these inequities. Here we present a case study of a phase III malaria vaccine clinical trial. 
Through qualitative interviews with researchers and caregivers of pediatric participants we 
elucidate rules that should shape the emergent behavior of the clinical trial system. Respondents 
from both groups reported financial and social contextual realities to be major drivers in the 
system. Specifically, we found a strong historical path dependency in the community that was 
closely tied to the relationships with researchers and indicative of the structural inequities. We 







Clinical trials in low-resource settings have rigorous ethical, protocol and regulatory 
requirements to adhere to when conducting their research (van den Berg, Machteld et al., 2019). 
On the other hand, the research sites where clinical trials take place contain human communities 
that have webs of complex social networks. The communities are dynamic with changing 
adaptive community systems which pose challenges for researchers, research participants and 
other community members to operate within the demands of the formal clinical trial 
requirements (van den Berg et al., 2019a; van den Berg, Machteld et al., 2019). 
The extensive regulatory requirements and complex social networks that make up both the 
clinical trial and the human community intersect during clinical trials, this leads to an expansion 
and interconnectivity of actors within the clinical trial system (Montgomery & Pool, 2017). 
Therefore, upon the initiation of a clinical trial in a low-resource setting, that human community 
becomes a part of the clinical trial and can be seen as one system (van den Berg, Machteld et al., 
2019). Complexity theory is an explanatory framework that can be used to model this new 
clinical trial system, which provides a conceptual toolbox to best adapt to the non-linear reality 
of working in human social systems (Sawyer, 2005).  
 
This newly expanded clinical trial system is guided by a set of rules that shape the dominant 
patterns among the agents in the system, relevant for both the researchers and the community 
where the research is taking place (van den Berg, Machteld et al., 2019). These simple rules are 
not classical cognitive and linear rules guiding behavior, instead they describe a collection of 
patterns that emerge from the system as a result of numerous feedback loops (Gomersall, 2018). 
Elucidating these simple rules for operating in low-resource settings can enhance ethical clinical 
trial conduct. Here ethics guidelines that consider the system’s complexity can be conducive to 
clinical trials in low-resource settings. The Council for International Organizations of Medical 
Sciences (CIOMS) guidelines provide well-reasoned answers to ethical dilemmas in these 
settings, and further guidelines are not necessarily the answer for better research conduct. 
However adaptive tools that are responsive to context can support local researchers to adapt to 
the problem of the unpredictability associated with working in social systems (Gauri & 
Khaleghian, 2002; Nichter, 1995; Stanton, 2004; Streefland, 2003b; Zimet, Liddon, Rosenthal, 
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Lazcano-Ponce, & Allen, 2006). Here we aim to complement existing guidelines through 
providing the tools to gain a thorough understanding of the patterns that emerge and the simple 
rules guiding behaviour upon the initiation of human research in low-resource settings.  
 
Through understanding the simple rules that guide the clinical trial system, feedback loops and 
the corresponding emergent iterative behavior can be better predicted (van den Berg, Machteld et 
al., 2019). We will examine clinical trials in low-resource settings through the lens of complexity 
theory (Braithwaite et al., 2017; Capra et al., 2009; Holland, 2014; Neely, 2015). First, we will 
outline the attributes associated with complexity theory and the clinical trial system. Second, we 
will present our case study focusing on experiences of two main actors, caregivers of participants 
in a pediatric clinical trial and the researchers conducting the clinical trial in the social 
community. By presenting the case-study from two different perspectives, we are seeking to 
provide a balance between the different themes that arise (Mkhwanazi, 2016). And third, we will 
discuss the simple rules and their implication for future clinical trial design in low-resource 
settings.   
 
Complexity Theory and Clinical Trials 
 
Clinical trials operating in human communities do not rely exclusively on standard operating 
procedures (SOPs) to define all details of community engagement. This is due to the complexity 
of operating in human social systems with numerous interconnected networks. The system 
adapts over time to its feedback loops and their interactions, making the prediction of its 
trajectory extremely difficult due to the vastness of the individual elements that make up the 
system (Braithwaite et al., 2017). Input A will not always lead to output B and can therefore not 
be predicted in a mechanistic way feasibly detailed by a standard operating procedure. 
Complexity theory provides a new paradigm of approaching this problem of unpredictability 
through providing an overarching explanatory framework. Fixed SOPs have a specific aim in a 
clinical trial and are written to be applied to a broad audience, they are therefore insufficient in 
predicting the precise behavior of a clinical trial system operating in a human community. 
Complexity theory can provide a model to promote adaptability and embrace the unpredictability 
through identifying the more patterned rules that guide the system (Braithwaite et al., 2017).  
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Complexity theory arose out of an array of different fields simultaneously, ranging from biology 
to economics to computer science (Holland, 2014).  According to complexity theory, complex 
adaptive systems (CAS) exhibit patterns of non-linearity, unpredictability, openness, 
interdependence and emergence (Neely, 2015). This non-linearity is a result of the actors within 
the system adapting to emerging circumstances. As a result, a CAS model will not provide a 
mechanistic answer detailing the step-by-step design of a clinical trial. It will, however, provide 
a framework to accept the tensions and paradoxes inherent in clinical trial research and a means 
to accept the uncertainty (Braithwaite et al., 2017). While linear rules cannot be applied to a 
CAS, the retrospective identification of simple rules can better predict emergent 
behaviour.(“Simple Rules,” n.d.) Complex adaptive system theory is therefore a useful 
framework to understand both human communities and clinical trials, which become one system 
upon the initiation of the study (Capra et al., 2009; Gilchrist, 2000; Luhmann, 1995; McDaniel, 
Driebe, & Lanham, 2013). CAS can be applied as an explanatory model to understand the nature 
of each system and elucidate the system’s actors and rules guiding the behaviour (Neely, 2015; 
Ramalingam et al., 2008; Sawyer, 2005).  This can support clinical trial researchers when 
responding to unpredictable pressures in an iterative, dynamic and interdependent manner (Khan 
et al., 2018).  
 
Presently, clinical trial design assumes that the clinical trial and the human communities in 
which they operate function as independent systems. Through approaching clinical trial design 
that views the two systems more holistically, we propose that less conflicting situations will 
arise, and the human community and research team can have a more synergistic relationship in 
the context of the clinical trial.  
 
To further detail this we will look at the human community and clinical trial through the lens of 
complexity theory. Research traditionally looks at community engagement as a tool to strengthen 
recruitment and retention in research studies (Johnson, Joosten, Wilkins, & Shibao, 2015). 
However, clinical trials embedded in human communities have more complex realities that 
extend beyond these components (van den Berg et al., 2019b). The formation of an expanded 
CAS upon the initiation of a clinical trial has implications for the community and for the 
 93 
researchers. To understand these implications, it is important to explore the clinical trial system 
from the perspective of both the research team and the human community where the participants 
live beyond enrollment and retention numbers.(Mkhwanazi, 2016) In line with this, we have 
conducted a case study of a phase III clinical trial operating in low-resource settings.  
 
Case Study: RTS,S Malaria Vaccine Phase III Clinical Trial 
 
The case study looks at a phase III pediatric malaria vaccine clinical trial. This trial is multi-
national and must adhere to stringent regulatory demands consistently across diverse health care 
systems and social systems.(RTS,S Clinical Trials Partnership, 2015b) Here we investigate the 
participant experience in Tanzania and Kenya, as well as the experience of the research team in 
Kenya. This clinical trial is now being  extended in Kenya into a pilot implementation with the 
clinical trial team continuing to operate in the community.(WHO, 2018a) This provides a unique 
opportunity for continued monitoring of the emerging clinical trial system and the implications 
the trial and the human community have on one another. The findings will inform future clinical 
trial research design in low-resource settings and provide insight into a viable path towards 







The expanded study design and methodology have been described earlier (van den Berg et al., 
2019a; van den Berg, Machteld et al., 2019). To understand the priorities and experiences of both 
the clinical trial researchers and the human communities where the pediatric participants live, we 
conducted a series of in-depth interviews with members of the RTS,S research team and parents 
of participants in the RTS,S phase III clinical trial. RTS,S malaria vaccine phase III clinical trial 
took place between 2009-2014. It was carried out in 7 African countries and 11 clinical trial 
centres (RTS,S Clinical Trials Partnership, 2015b). We selected participants from three clinical 
trial centres in Tanzania and Kenya, and members of the research team from two clinical trial 
centres in Kenya. These sites were chosen due to their geographical proximity, but different 




Interviews with parents were held in the home of the participants. Interviews with the researchers 
were held at the research site of the clinical trial. All interviews were held between March 2017 
and March 2018. Respondents were selected based on their participation in the phase III RTS,S 
malaria vaccine clinical trial. Interviews with caregivers of participants were conducted together 
with local, bilingual research assistants and the first author. Interviews with researchers were 




Interviews with parents of participants were recorded, transcribed verbatim and then translated to 
English. Interviews with researchers were recorded and transcribed verbatim. Analysis was 
initiated immediately following the interviews and MAXQDA software was used for line-by-line 
microanalysis of the interviews, followed by thematic coding. All coding was done by MV and 
selected parts of the coding was reviewed by SM. The focus of the analysis was on the changes 
in the community upon the initiation of the RTS,S clinical trial, the relational dynamics between 
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researcher and community, and the perspective of both the researcher and the community on the 




Informed consent was obtained before each interview was conducted. The recorded audio, 
transcripts and participant information were stored separately in password protected files. All 
interviews were anonymized.  
Ethical approval for the study was obtained in Tanzania (i) from the National Health Research 
Coordination Committee of the National Institute for Medical Research (NIMR) through the 
Tanzania Commission for Science and Technology (COSTECH) and Ifakara Health Institute 






The results presented here relate to other work in the context of a larger project (van den Berg et 
al., 2019a; van den Berg, Machteld et al., 2019). There were a total of 55 in-depth interviews 
with parents of participants in the three selected sites as follows: Tanzania (n=18), Site 1 in 
Kenya (n=20) and site 2 in Kenya (n=17). The average interview lasted about 29 minutes, with 
the longest being 45 minutes and the shortest 20 minutes. The duration of 7 interviews could not 
be included due to logistical constraints as the original audio files were erased after transcription. 
There were 11 interviews with the researchers and each lasted on average 53 minutes, with the 
longest being 2 hours and the shortest 28 minutes. 
 
During our interviews the complexity of the clinical trial system was repeatedly identified. In 
particular it was reported by the researchers that the clinical trial system is non-linear and 
requires adaptation to each unique context. This is illustrated by the quote below from a 
researcher describing their experience in the community as a clinical trial researcher: 
Researcher 11 It is not a straight line that will be smooth all the time. You may 
have challenges that will be different with every study. 
Drawing on this non-linearity, we identified recurrent themes in both groups of respondents. The 
factors driving the emerging behaviour of the clinical trial system that were frequently reported 
were blood draws, participation benefits, community influencers, finances, communication and 
health. There was a strong overlap between the two groups of respondents in themes identified. 
However, the caregivers reported more concern with the financial and health contexts. The 
researchers had a greater emphasis on the consequences of communication and the relationships 
built during the conduct of research in a community. Both placed a heavy emphasis on blood 
draws and the role they played in the clinical trial system. Here we present these themes with 




Almost all caregivers and researchers in Kenya reported concerns raised by the community 
concerning blood draws. In Tanzania it was raised less often as a concern although they 
identified this, along with the associated rumours, as the leading issue in the clinical trial. It 
affected community perception, relationships with the researchers and trial enrollment.  
Researcher 08: The main issue in the community is about blood samples that we 
take. People want to know “what are you doing with the blood?” someone could 
be on the road and tell you “I heard you people are doing research and you are 
collecting blood samples”. This is someone who is not participating but is part 
of the community and they want to know what you are doing with the blood. 
Caregiver 32: Excess blood draw was done where the vaccine was administered. 
People ran away because of the excess blood draws. 
During interviews the caregivers in Kenya reported the term “Logo rembji” meaning “taking 
people’s blood in excess”. It was reported to be associated with members of the research team. 
Respondents described that some community members suspect researchers of entering the 
community, enrolling participants in research, withdrawing the blood and draining it without 
their consent. It is then suspected of being sold or used for satanic purposes. In the context of this 
pediatric trial, it led to the suspicion that the children enrolled will get sick and then not respond 
to treatment in the hospital.   
Caregiver 01: Sometimes when someone came like the way you have come now, 
then someone just tells you that “No! No! No!  I don’t want a researcher near 
me! No! A research person will ‘Logo rembji’ I don’t want them”.  
Caregiver 19: People are saying that some people have given their children’s 
blood which is being taken to the devil. The devil takes their blood. But they say 






The benefits associated with participating in research, specifically the free medical care and 
transportation to the research facility, had a powerful impact on the clinical trial and how the 
community responded to it. Researchers identified this and linked it to how it strengthened the 
relationship with the community and the community engagement that is also outlined in the trial 
protocol.   
Researcher 03: The community feels that at least the researchers don’t just come 
and get our blood, do their research and go away. At least there is not only 
community engagement, but also a benefit to the community in several ways. 
Both groups of respondents identified the influence that benefits had in building a rapport with 
one another. Furthermore, almost all respondents emphasized the impact played by the manner in 
which the benefits were provided. When the participants and their caregivers were treated 
warmly and with respect, this had a significant impact on the experience that the community 
members had with the clinical trial. 
Caregiver 33: What I would say is that they took good care of us, accorded 
respect, there was good rapport, the study staff would welcome us warmly as we 
were part of them. We would be welcomed more warmly in the study than the 
government clinics. We were delighted in the way they handled us. 
 
Influencers and gatekeepers 
 
There are a number of actors in the clinical trial system that respondents identified as having 
more influence on the clinical trial system than others. In particular, mothers-in-law were often 
singled out as being opposed to or supportive of the research and depending on their position, the 
grandchild would or would not be enrolled. This was the case even when the mother was the 
primary caregiver and the individual formally consenting.  
Researcher 08: In some cases, you would find that the mothers-in-law had a lot 
of say on if the participant is going to participate in the study. In some cases we 
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would find that someone would decide to withdraw but the reason they withdraw 
is because they were influenced by the mother-in-law. We find the religious 
background and the mother-in-law probably don’t accommodate some of the 
things that they felt we were doing. So I would say that in this area, in some 
cases, you would find that the mother in laws or even other people who are not 
the parents, had say on whether those people would participate. 
Caregiver 25: I was not ready stating to my mother-in-law that the research is 
known to draw a lot of blood from children. My mother in law encouraged me, 
saying that the child will benefit a lot not only against malaria but against all 
other diseases that may come up. They came back, and I allowed my child to be 




Frequently it was highlighted by respondents that having a relationship with one another as 
human beings was a large part of the trial. This was emphasized consistently by caregivers as 
being positive and it made the research more easily accepted in the community.  
Caregiver 47: They were humble and they loved children, that is the uniqueness. 
Researcher 02: Don’t treat them as a subject, treat them as someone who has 
sacrificed their time who has put aside some of the things they were supposed to 
do to come to the research centre. 
The researchers identified the role that relationships with participants and their families played in 
many aspects of the trial. Including enrollment, retention, adherence to scheduled visits and 
minimizing rumours. However, there were also drawbacks for the researchers when they became 
emotionally involved, in particular when a participant became critically ill and died during the 
clinical trial. This was an emotional burden and required the researcher to grapple with the 
multiple roles they have as a member of the research team and also an individual deeply 
embedded in the community due to the research.  
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Researcher 11: When you go home and sit and you now analyze how it was in 
the day, and it is like, surely did I help that family? Did I help? It haunts you if 
you did not really do well. It makes you feel bad. You want to get them the next 
day to see how they are. Because once in a while a participant died and when 
the participant dies you want to console them. It is difficult as a person, as a 




Participation in the trial was often identified by caregivers to be linked to their lack of financial 
resources. This was a strong factor in the clinical trial system, encouraging participation in the 
research as the free medical care relieved a financial burden when the child would fall sick. From 
the researcher’s perspective, alleviating the financial burden in this way was framed as 
conducive to community engagement as it brought the researcher into deeper relationship with 
the community.  
Caregiver 35: The people were enrolled praised the study. Most of them are the 
people who come from around who earn a little money. Sometimes when the 
child falls sick it becomes difficult especially for us who are farmers. 
Researcher 02: Another thing that motivates them to come, is the transport 
reimbursement and paying for inconvenience. You also pay for that time, so 
these are mothers who would not go to the farm that day, these are mothers who 
would have gone to the market to sell their produce but they are spending their 
day at the facility. So try to compensate that way, they feel like you are thinking 
about them, you are thinking about the time they are spending with you. 
 
The clinical trial alleviated the financial burden, when it ended it created tensions when other 
children could not receive the same benefits as past participants. The caregivers were still subject 
to the structural inequities and had to once again use their money to pay for the care when their 
children fell sick.  
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Caregiver 13: The researchers have left us but I still need them. 
Caregiver 21: I didn’t want it to end, it’s the ending of the study that I didn’t 
like. I just want the children to continue with it.  
This created moral distress in the researchers, to the point where they reported using their 
personal money to finance needed medicines for children from the community.   
 Researcher 11: Once in a while I can even take them, have the clinician 
prescribe and I buy drugs for them on the clinics outside. Sometimes I just ask 
the clinician to check, then whatever they have prescribed I can walk across, 




The role that communication played in building trust was highlighted in most interviews, from 
both groups of respondents. It was identified to be the foundation on the which the engagement 
with the community was built. Communication was a factor in the trial system that reduced the 
spread of rumours, strengthened understanding, protected the integrity of the data and a sense of 
trust between the two groups of respondents.  
Caregiver 19: The researcher who came to me talked very well with me. She 
taught me and explained that even if people are talking that way, it’s not that 
way. She talked to me very well and I agreed.  
Researcher 09: The minute we don’t give the right information, the minute there 
is no trust, then it means even the investigators will not trust on the information 
that is being generated. And that will affect data. So it can affect the data and 
also our trust in the community and maybe future interactions with the 
community. 
The caregivers also identified instances where communication between the research team and 
themselves failed. For instance clarifying the terms of the consent and the timeline of the study. 
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This then affected the overall way in which research was perceived by the community and 
thereby future interactions. 
Caregiver 29: Towards the end of the study, the study developed a weird 
behavior. They would ask the reason for your going to the clinic. You would be 
discouraged and wonder why they behaved in such a manner - not being treated 
with respect. The doctor would take more time before attending to you. I didn’t 
like that. I like that after people consent to do something, they do it from 




The health and well-being of the pediatric participants was a priority for all of the respondents. 
This is related to the financial burden above, as caregivers in poverty struggled to access medical 
care for their children in the absence of a clinical trial. Having the possibility to deliver needed 
clinical care provided relational motivation for the researchers and fulfillment in their work. It 
created trust between the caregivers and the researchers, which spread into the community.  
Researcher 02: It was fulfilling, most of the mothers were happy in the trial. 
Their reasons being their children had access to medical care, without the trial 
they would not have access to the medical care. During the vaccine study, 
whenever their children felt sick irrespective of the condition, we would offer 
them care. So those children who had road accidents or trauma injury would 
have their bone fixed and surgeries were done so they were happy that they 
benefited, their health improved and they were willing to come back. 
Caretaker 40: I knew my child will get better treatment and medication. Before 
the trial we were given a bottle of medicine and had to share it with four people 
but when I joined the trial I was getting a bottle and could open it when I got 
home. 
Researcher 09: The fact that we saved many lives was motivating both for us and 
the community as a whole. 
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Caretaker 25: I didn’t experience any negative side of the research. It was all 
goodness. I received aid from January, receiving free medication for my child 
until the end of the year. I just said thanks to the research team. I still have 
young children wondering when again they will be enrolled into a study so that I 
benefit as I had benefited from the past. 
Providing medical care for participants generated a positive relationship between researchers and 
the community. However, in serious cases when a child not eligible for the clinical trial fell ill 
the caregiver would come to the clinical trial centre needing medical attention – this would 
create challenges for the research team. As the researchers have to balance their accountability to 
the sponsor with their role in the community and have limited financial resources.  
Researcher 11: We told them we will only treat the participant and the budget is 
so stringent that it can only treat the volunteer. We don’t want to have extra 
patients, you see. We budget strictly according to the demands of the study 
because of finances and sponsor. So if you open the door everybody will come. 
But if you do not treat and you refer them to the government facility and they 
eventually die and they are not in the study, then you are in trouble in that 
village. You can’t even attend that funeral because you neglected them. And 
even in the future if you go recruiting for another study, adult or whatever, in 
that village they will tell you “no last time you refused to help our child and the 
grave is there, you can look at the grave” Then you really feel funny. So you 
really must be very careful. You may go an extra mile and treat and tell them, in 




The main factors influencing the clinical trial outcome highlighted by both the researchers and 
caregivers have been listed in Table 1. The corresponding simple rule has been developed based 
on the qualitative analysis of the main themes and relevant literature to the contextual setting. 
The respondents described emergent behavior of the clinical system and the ways in which the 
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trial design best supports harmonious relationship between the researchers, the caregivers and 




Factor Simple rule Application for trial design 
Past Research 
Experiences 
The human community has a historical 
path dependency. Heavily context 
dependent. 
Map historic context and 
integrate into the clinical trial 





Balanced benefit-sharing between 
participants and the research team 
reflects mutual respect and harmony in 
the clinical trial system. 
 
Build a relationship where each 
group gets what is required and 
can contribute where their 
expertise lies. 
 
Social Influencers Family and community members have 
opinions that influence enrollment and 




Identify the whole system and 
its parts. See where factors and 
actors are interconnected and 
recognize the interaction 





Human relationship plays a major role 
in system emergence. 
 
Identify how positive emotions 
and social norms of reciprocity 
drive adaptive capacity in the 




The economic context influences 
informed consent practices and also the 
moral distress of researchers. 
Heavily context dependent. 
Recognize the economic 
context of the clinical trial 
system and provide flexible 
options for researchers 




Ongoing, transparent communication 
leads to a positive perception of 
research in the community. 
 
Design a communication 
strategy that is sensitive to the 
other factors identified relevant 
to the system and apply it in an 
iterative, transparent fashion. 
 
Access to health 
care services 
Good child health is a priority for all 
identified actors in the system. 
Enable researchers to provide 
care on humanitarian grounds 
for critical cases.  
 
Table 1. Factors identified by caregivers of pediatric participants and researchers conducting 
the clinical trial as shaping the clinical trial system.  
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DISCUSSION AND RELEVANCE 
 
There were significant overlaps in both groups of respondents on the identification of factors that 
impact the clinical trial system. This alignment is likely indicative of the setting and the five 
years that the clinical trial operated in these communities. These results provide new insight into 
the implications of clinical trial systems merging with human social communities. Based on the 
factors identified by both groups, engaging with the community has large implications that 
extend beyond strengthening recruitment numbers in the clinical trial. The simple rules 
highlighted above shows the extent of the relationship between the trial and the community, as 
well as the ways in which these can be integrated into clinical trial design.   
 
The simple rules highlighted in Table 1 are developed to encourage participatory exchange 
between the various actors in the clinical trial system. It is important to clarify that the simple 
rules do not predetermine the exact emergent behavior of the system, as each situation and 
context is different. Instead this map of simple rules is intended to be used as a supplementary 
tool that researchers can use to interact with communities in an iterative manner to complement 
existing ethics guidelines like CIOMS and regulatory requirements such as those described in 
SOPs. Standard practices in clinical trials focus on protecting autonomy and ensuring consent is 
free and informed. However, this is challenging in low-resource settings where structural 
inequities may impede free choice due to a lack of viable medical options outside of the trial. 
 (Kingori, 2015). Through the use of the proposed rules, clinical trials can understand these 
contextual realities and respond by working with local leadership to generate medical options if 
necessary.    
 
While there was an overlap in the identification of factors, each group weighed the influence of 
these factors on the system’s processes differently. The caregivers spoke more frequently about 
the financial burden they as caregivers carry and how it was alleviated by the free health care 
provided by the clinical trial. Similar results have been reported by other research in these 
settings (Haire & Ogundokun, 2014; Paré Toe et al., 2013). The researchers viewed 
communication and human relationships as key factors in the emergence of the clinical trial 
system. Both placed a similar emphasis on blood draws and the surrounding suspicions.   
 107 
 
The difficulties surrounding blood draws in Kenya and Tanzania have been identified elsewhere 
(P. Wenzel Geissler, 2005; Vallely et al., 2007). The concerns around blood draws are rooted in 
real historical experiences with research and exploitation (P. W. Geissler & Pool, 2006; 
Graboyes, 2015). Through the lens of CAS theory, these experiences are indicative of a historical 
path dependency exhibited by the system – where past research experiences influence the present 
state of the system. The ways in which the hesitancy surrounding blood draws were reported by 
the caregiver and researcher was different. The caregivers experience pressure from the 
community and family to avoid research due to this, which was expressed as concern for the 
welfare of the child. Furthermore, often the caregivers themselves have concerns about the 
impact that the lost blood will have on the child’s health. The researchers described concern 
about blood draws as a lack of education and cognitive understanding on behalf of the 
community and caregiver. This is also related to historical myths of those who move around the 
community and night accosting people and draining their blood for sale or cultic rituals. This 
disconnect, if unaddressed, can lead to further skepticism and affect the clinical trial from 
moving forward successfully (Kingori et al., 2010). In clinical trial design, this can be addressed 
by identifying the historical path dependency of the human community a research team is 
working in. For instance, participatory techniques to promote an understanding of the community 
research experiences and appreciation of what happens to blood that is taken from a participant 
have been successful in microbicide clinical trials in Tanzania (Vallely et al., 2007).  
 
The interrelatedness between factors was also evident. For example, finances and health care 
exhibited a dependent pattern with one another. The more a caregiver spoke about finances, the 
more they also reported valuing the health care provided. The relational factor and social 
influencers also displayed significant interrelatedness, from relying on members of the research 
team with strong relational skills to identify the social influencers in the community to the 
importance of relational skills with regards to factors such as communication and benefits. 
Valuing human relationships and having strong relational skills as a researcher was reported to 
be important for communicating clearly with the caregivers. And in both Tanzania and Kenya, 
caregivers valued the relational skills of the researchers when they provided quality care. 
Caregivers highlighted how they valued a researcher who made them, and their children feel 
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comfortable and clarify the kinds of benefit expectations they should have from the research 
project. Inversely this was true too, in cases where respondents reported being disappointed by 
the project, it was frequently a result of a disconnect due to poor communication skills around 
the kinds of benefits participants and caregivers expect from the study.     
 
This difference also brings us to the ways in which each group weighed the factors that dictate 
the emerging patterns of the clinical trial system. Each is rooted in the contextual reality that they 
inhabit, but this is particularly true for the historical and financial factors. The caregivers are 
living in a low-resource setting and view the research study as the high-capital resource that can 
alleviate the burden they face when a child is sick, which is central to their life. The researchers 
are predominantly speaking from the historical experience in the context of their professional 
role during the qualitative interviews. They therefore identify their contextual experiences where 
communication was transparent and successful as being the main driver of clinical trial system 
emergence. Speaking from their role as a clinical researcher, they expressed their relational 
fulfillment in providing medical care and healing the participants in need of medical attention, 
central to their professional ethic. To be able to adapt to the contextual differences, clinical trial 
design needs to encourage research teams to work with communities in an iterative fashion. This 
is of particular relevance when the clinical trial site hosts numerous trials over a longer period of 
time, encouraging ongoing and adaptive interaction. Each of these factors and simple rules 
influence feedback loops within the system, which vary depending on the context. The 
interrelatedness identified showcases the importance of a wholistic approach, paying careful 
attention not to negate different perspectives across roles (researcher and caregiver).  
 
Transnational clinical trials in low-resource settings have unique challenges, many of which fall 
on the shoulders of the local researchers (Crane, 2010; Merritt, Taylor, & Mullany, 2010). 
Researchers reported this struggle, with one expressing “it is difficult as a person, as a human, as 
a mother” when speaking about the conflicting duties towards the community, the research 
institution and the social relationship. The capital discrepancy in low-resource settings between 
the clinical trial and the community often has researchers facing a moral dilemma. In this case 
study, it led to the use of their personal finances to support caregivers when seeking medical care 
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and distress when faced with professional obligations that were not socially accepted in the 
community.  
 
Through designing clinical trials that operate in local communities, using CAS as a framework to 
better predict the unique system emergence, some of the burden on researchers can be alleviated. 
This will mean equipping research teams with the possibility to operate in iteration with 
reflexivity, adapting to the local setting and progression of feedback loops in the system. Ethics 
committees can support this by acknowledging the non-linearity of the process, promoting the 
identification of the feedback loops and application of these simple rules to clinical trial design 
preemptively. Simple rules that are designed around research experiences, benefits, social 
influencers, relationships, finances, communication and health care must be incorporated from 
the start of the clinical trial in the community, when the system forms a new CAS. When the 
project initiates, the identification of the interrelatedness between these factors it will also help 
researchers fine-tune the iterative process to their local context. These factors should be 
considered by researchers at the beginning of the trial and applied based on their relevance for 
that contextual setting - enabling researchers to better respond to the non-linear nature of 




This study elucidates that the implementation of a clinical trial is heavily influenced by the 
complexity and unpredictability of the human social system, which thus makes it difficult to 
implement procedural and ethical requirements which do not give room to respond to the 
highlighted implementation challenges. Supplementing regulatory requirements with clinical 
trial design that encourages iterative processes can address some of these implementation 
challenges. For example, allotting time for the clinical trial team to meet and discuss the iterative 
process and make amendments to the process as necessary. The simple rules highlighted here 
should be used as a tool to guide exchanges between actors in the clinical trial system and inform 
the design of the clinical trial. Future research should establish the use of these simple rules 
across different contexts and assess the impact of integrating them into the design on clinical trial 













In this section I highlight the findings from the papers and explore the ethical implications of the 
results from the compiled empirical data. Drawing on my findings, I conclude that clinical trials 
are complex adaptive systems that need to be sensitive to the contextual realities of the human 
communities within the system and subsequently describe how to integrate this into clinical trial 
design. I will begin by exploring these realities, for both the caregivers and human participants and 
then the researchers on the frontline of the clinical trial. Then I will discuss the role of relational 
ethics in supporting frontline researchers and enhancing caregiver agency. And finally, I will then 






CONSENT AND CHOICE 
 From the empirical paper, Clinical trials in low-resource settings: the perspectives of 
caregivers of paediatric participants from Uganda, Tanzania and Kenya, the provision of medical 
care created, at times, an undue inducement. What was exceptionally evident during the systematic 
analysis of the qualitative data was the frequency with which caregivers spoke about their 
participation in relation to their gratitude for free medical care provided by the trial. This extended 
into community decision-making and acceptance around the presence of the trial, as discussed in 
the paper. The low-resource context has been shown to influence the ways that risk is interpreted 
by those consenting to participation in research (Cottingham & Fisher, 2016; Walker et al., 2018). 
The use of a framework for the analysis was intended to capture this context and understand the 
multidimensionality of the embodied caregiver.  
 
 Figure 1. Framework for analysis outlining the interplay between community, domestic and trial 
contexts that the respondent inhabits and the economic, political and social realities of the 
embodied respondent. 
 
 By understanding the caregiver from the social, economic and political context - choice 
can be better understood and its interplay between the different realities that a caregiver and 
participant inhabit. I learned through the interviews that each reality has a significant impact, as 
is highlighted in Clinical trials in low-resource settings: the perspectives of caregivers of 
 117 
paediatric participants from Uganda, Tanzania and Kenya, however the economic state of many 
caregivers resulted in the negation of risk when caregivers were offered free medical care.  
 
 From this, it is possible to conclude that the provision of medical care can significantly 
hamper choice and caregiver autonomy. This has been raised as a challenge in research with 
human participants in low-resource settings when the services offered by the institution far 
surpass the local health services (Mtove et al., 2018; H. T. Shapiro & Meslin, 2001). Others have 
even argued that the decision to participate in research has been made before the risks have been 
clarified during the consent process (Paré Toe et al., 2013). This brings forth difficult questions 
concerning autonomy when the only means for caregivers to provide needed health services to 
their child is a clinical trial.  
 
Should we do research when choice is diminished? 
 
 I began this thesis framing my questions around the foundational bioethical principles 
and here I will come back to that. Specifically, looking at the role of autonomy and its relevance 
to choice and informed consent with regards to the understanding of risks and benefits of 
research participation in low-resource-settings. One of the aspects I raised in the introduction 
was the differences between the social systems, where individual autonomy reigns in Western 
countries, there is a greater focus on the collective social system in the low-resource settings 
studied. It has been argued that the emphasis in clinical trials on individual choice neglects the 
different social and structural contexts that are common in low-resource settings (Gikonyo et al., 
2008; Kingori, 2015; Molyneux, Peshu, & Marsh, 2004). Through my interviews I also 
encountered the prominence of collective decision making and the role of extended families to be 
very different from the Western values I am accustomed to. Therefore, first I will consider these 
differences and what that means for choice.   
 
 Through my interviews with the caregivers, there was often the theme about the role of 
their extended families, neighbours and community leader in their decision making. And as I 
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raise in the paper, Clinical trials in low-resource settings: the perspectives of caregivers of 
paediatric participants from Uganda, Tanzania and Kenya, this is an important aspect of 
community acceptance of the research taking place and strengthening trust between researchers 
and the community members. Therefore there must be extra care paid to community engagement 
practices that extend beyond the individual caregiver to ensure that the correct information is 
reaching all for those involved in the collective decision making, this can foster autonomy in a 
setting where the locus of decision making is communal without compromising the principle of 
informed consent (IJsselmuiden & Faden, 1992).  
 
 Another consideration I deem to be even more pertinent to choice, based on my 
qualitative data, is the glaring structural disparity between the clinical trial health services and 
those accessible to caregivers outside of the trial. This is a key dimension when it comes to 
assessing autonomy and informed consent (Kingori, 2015; Mtove et al., 2018; Paré Toe et al., 
2013; H. T. Shapiro & Meslin, 2001). As many caregivers in this project discussed their decision 
to enroll in the trial, they spoke of having a sick child and no money to provide medication or 
having access to the required services to treat the child. In some cases, this was the moment they 
decided to enroll in the trial. Having to consent to research without alternative options has been 
termed the ‘empty choice’ (Kingori, 2015). What I found through the interviews is in line with 
what others have discovered, having an ill child makes the caregiver more likely to consent to 
the research and this raises some red flags and demands further reflection on the role of the trial 
in our setting, East Africa, and the duties of the trial in relation to these structural inequities (H. 
R. Fisher et al., 2011). 
 
 Implementing a clinical trial in these settings may not remove autonomy, instead I think 
that drawing the link between free medical care and the absence of autonomy is an over-
simplification. Autonomy is certainly restricted, however this existed in a temporal space before 
the action of medical research and when a child falls sick the consequences are witnessed with or 
without the presence of a clinical trial. The caregiver’s will to keep the child healthy is there, 
however the only existing choice to do so may be enrollment in the clinical trial. Therefore, 
autonomy is profoundly limited as a result of these perverse structural inequities that frame the 
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parameters of choice in everyday life for those living in severe poverty – something referred to 
as structural coercion (Farmer, 2004b, 2004a). In our study the research does not remove agency, 
structural disparity does. Paul Farmer frames this accurately when speaking of inequities in low-
resource settings: 
 
“Their sickness is a result of structural violence: neither culture nor pure 
individual will is at fault; rather, historically given (and often economically 
driven) processes and forces conspire to constrain individual agency. Structural 
violence is visited upon all those whose social status denies them access to the 
fruits of scientific and social progress.” (Farmer, 2001) 
 
A conflict of principles 
 
Taking into consideration the structural disparity in these settings, we must also consider the 
consequence of not conducting research, choosing not to act is also action and further denying 
those with the highest need “the fruits of scientific and social progress”(Farmer, 2001). As 
described by Eisenberg “impeding medical research no less than performing it, has ethical 
consequences” (Eisenberg, 1977). Not conducting the medical research to develop a malaria 
vaccine (or another therapeutic targeting populations in low-resource settings) would allow 
hundreds of thousands of preventable deaths to take place while the resources are available to 
develop a preventative or curative tool. This consequence of inaction would further the “10/90 
research gap”,  a term coined in the 1990s to reflect that 10% of global research potential is 
devoted to conditions which make up 90% of the global burden of disease (Global Forum for 
Health Research Organization, 2004).  A less severe form of inaction, conducting the clinical 
trial but not providing medical care, would allow the suffering and preventable deaths to 
continue in these settings. In the case of the PMVT, the provision of care significantly reduced 
overall child mortality - with one of clinical trial sites in Kenya reporting a 70% reduction in 
mortality (Hamel et al., 2014). Therefore, providing medical care and saving lives is a way 
participants can receive immediate benefits from the research participation and may not 
necessarily constitute undue inducement (Haire & Ogundokun, 2014). While the preventable 
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death of a single child is horrendous, this reduction in childhood mortality is a benevolent act by 
the clinical trial – introducing us to the strings of an intricate web that accompanies ethical 
deliberation between the principle of beneficence and the principle of autonomy. Determining 
the ethical course of action means to weigh and balance these ethical principles and then to 
substantiate this action through supportive moral reasoning. 
 
While there are concerns around autonomy during the conduct of trials in these settings, the 
beneficence associated with conducting the research may outweigh this inherent limitation on 
autonomy. Consider this same situation of child mortality in a developed country, if we would be 
experiencing this volume of preventable deaths in the Swiss countryside we would immediately 
mobilize and fund this research even if participation in the research was not fully autonomous for 
the children. Perhaps there is no moral distinction between the imperative to act, only a spatial 
one. Performing clinical trial research in low-resource settings has ethical challenges as it is 
difficult to restore autonomy in a setting where the structural violence is such that autonomy is 
frequently stripped away. But not conducting the research and not acting allows for the disease 
burden to be remain.  
 
With a pragmatic aim of better health and well-being, we are seeking the summon bonum, 
highest good, and must therefore uphold the foundational principles of biomedical ethics. 
Through the conduct of clinical trials in low-resource settings targeting diseases endemic to 
those regions we are on such a path, yet the upholding the principle of autonomy is arguably the 
most challenging in this task. To develop a justifiable conclusion, we need to discuss how to 
protect autonomy. According to individual centered rule-utilitarianism “over himself, over his 
own body and mind, the individual is sovereign”(Mill, 1859) which emphasized the principle of 
autonomy and its role in moral theory, the greatest good should be pursued while concurrently 
upholding autonomy. This notion in the context of utilitarianism is a narrow perspective on 
autonomy and to supplement it we must understand the role the clinical trial stakeholders can 





How to address diminished choice? 
 
While the aspiration to remove structural disparity from our world is a worthwhile one, to 
demand the clinical trial to remedy global injustice before conducting research is an over-
extended expectation that will have an inhibitory effect on research benefiting vulnerable 
populations. Nevertheless, clinical trials operating in these settings do have an ethical obligation 
to prevent exploitation in their research settings. Victims of structural disparity are certainly 
vulnerable and vulnerable populations are at risk of exploitation (Macklin, 2003). Proposing to 
reinstate autonomy by addressing the lack of knowledge ignores this vulnerability and instead 
diverts attention away from the lack of options which is underpinning the restriction of 
autonomy. As our qualitative interviews indicate, caregivers without medical access and sick 
children have sufficient knowledge to know that enrolling in the trial is their only viable option 
to ensure the survival of their child. Their decision is not based on a lack of will or knowledge, it 
is based on a lack of choice. Thus, while the clinical trial is not responsible for rectifying global 
structural inequity, the lack of local medical infrastructure cannot be separated from the research. 
Due to this inextricability there is an ethical duty to address this structural inequity as it leaves 
participants and caregivers vulnerable to exploitation. To address structural inequity the clinical 
trial must address the lack of options in these research populations, this means to strengthen the 
quality of medical care options and increase the viable options available.  
 
There has been a discussion as to the medical care duties of clinical trials operating in low-
resource settings to the community and a number of guidelines have been produced (Table 1). 
For example, CIOMS in Guideline 21: “External sponsors are ethically obliged to ensure the 
availability of: health-care services that are essential to the safe conduct of the research; 
treatment for subjects who suffer injury as a consequence of research interventions; and, 
services that are a necessary part of the commitment of a sponsor to make a beneficial 
intervention or product developed as a result of the research reasonably available to the 
population or community concerned.”(Council for International Organizations of Medical 
Sciences & World Health Organization, 2002). The Declaration of Helsinki states in paragraph 
9: “It is the duty of physicians who are involved in medical research to protect the life, health, 
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dignity, integrity, right to self-determination, privacy, and confidentiality of personal information 
of research subjects.”. These guidelines are broad and open to different interpretations -  not 
providing a specific answer around the obligations of the clinical trial itself when this extends 




(Council for International 
Organizations of Medical 
Sciences & World Health 
Organization, 2002) 
“External sponsors are ethically obliged to ensure the availability of: 
health-care services that are essential to the safe conduct of the 
research; treatment for subjects who suffer injury as a consequence of 
research interventions; and, services that are a necessary part of the 
commitment of a sponsor to make a beneficial intervention or product 
developed as a result of the research reasonably available to the 
population or community concerned.” 
Declaration of Helsinki 
(World Medical Association, 
2013) 
 
“It is the duty of physicians who are involved in medical research to 
protect the life, health, dignity, integrity, right to self-determination, 
privacy, and confidentiality of personal information of research 
subjects.” 
 
Nuffield Council, 2002 
(Nuffield Council on Bioethics, 
2002) 
 
“The nature of care and treatment that will be provided to participants 
in research including preventive and curative treatments and diagnostic 
interventions” 
 “When research into preventive measures is conducted, wherever 
appropriate, participants who develop the disease being studied should 
be offered a universal standard of care for the disease being studied. 
Where it is not appropriate to offer a universal standard of care, the 
minimum standard that should be offered is the best available 
intervention as part of the national public health system for that 
disease”. 
US National Bioethics 
Committee: The Charter of the 
National Bioethics Advisory 
commission (NBAC) 
(National Bioethics Advisory 
Commission, 2001) 
“Treatment that is routinely available to the majority of the population 
of that country” 




“Participants who acquire HIV infection during the conduct of a 
biomedical HIV prevention trial should be provided access to 
treatment regimens from among those internationally recognised as 
optimal. Prior to initiation of a trial, all research stakeholders should 
come to agreement through participatory processes on mechanisms 
to provide and sustain such HIV-related care and treatment”. 
 
Table 1. An overview of the current recommendations on the extent to which vaccine trials should 
provide medical care.  
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 These guidelines are not step-by-step protocols, instead they are open to interpretation, 
need to be considered within the target context, and moral reasoning must be applied  
(Solomon R. Benatar & Singer, 2000).  
 
 There are expansive notions of what obligations sponsors have when it comes to 
strengthening the quality of medical care, with some suggesting they must meet all medical needs 
(London, 2005; K. Shapiro & Benatar, 2005). In the short-term, providing the gold standard of 
care for all community members free of charge is likely not economically feasible. However, the 
supplementation of clinical trial budgets to strengthen local health capacities for the community 
members will provide alternative options for caregivers and provide a more reasonable choice 
when deciding to participate in research. What needs to be done to restore caregiver autonomy is 
to provide care options for all children eligible for the trial that is context-specific. This will 
generate alternative options and thereby reduce the possibility of inducement related to the free 
medical care in situations where caregivers have an ill child.  
 
 The reduction of regulation around what constitutes medical care under the umbrella of the 
clinical trial and expanding this into the community will also generate quality medical care options. 
In HIV vaccine trials, sponsors must outline what medical care they will provide in the research 
protocol when submitting it for ethical review (UNAIDS/WHO, 2012). I propose that by outlining 
specifically what medical care will be provided and positioning it relative to the context of the 
local setting, RECs can determine if there is a need to strengthen the quality of medical care options 
outside of the trial before and during the research study. This encourages further collaboration with 
local stakeholders. Engagement with local stakeholders is important to identify the structural needs 
of a trial site and encourage the responsible stakeholders to contribute to strengthening these 
medical care options, these stakeholders range from national policy-makers to decision makers at 
the district level to local community members (Mtove et al., 2018). There is frequently competition 
between countries for clinical trials and this incentive, combined with national collaboration, can 
lead to local government commitments to strengthen medical services. Taking this approach and 
fostering good collaborative research governance can lead to the development of health systems 
sustainably (Ward et al., 2017; Ward, Shaw, Sprumont, et al., 2018). In the long-term, 
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strengthening the local health system and thereby improving the quality of medical options 
available to caregivers, reduces the structural inequities and strengthens caregiver autonomy.  
 
 The risk of placing these responsibilities on the sponsor or funder is that demanding such 
commitments can lead to an overextension of expectations and thereby inhibit research in these 
settings, especially for neglected tropical diseases, and we cannot stop doing research on these 
topics. Also providing care may have an inhibitory effect on local governments to invest in health 
system strengthening in these settings, who do ultimately have the duty of to meet local health 
needs (Georgetown University Workshop on the Ancillary-Care Obligations of Medical 
Researchers Working in Developing Countries, 2008). No one actor in the clinical should be 
responsible for rectifying the structural inequities by providing the highest possible care in a low-
resource setting, and while aspirational, we must strive for this care to be accessible for these 
populations. Therefore, clinical trials must engage in an equitable manner with stakeholders to 
improve collaborative practice and support local governments in strengthening the quality of local 
health services (Ward, Shaw, Sprumont, et al., 2018). The level of care provided and to whom will 
depend on various factors linked to the local contexts and the phase of the clinical trial, but the 
costs should be shared amongst stakeholders appropriately. This is succinctly put by Kleinman, 
saying that bioethics should “be the outcome of reciprocal, participatory engagement across 
different worlds of experience” (Kleinman, 1997). 
 
 What I hope to convey is the impossibility of an ethical manual providing straight-forward, 
linear instructions with regards to the establishment of choice or lack-there-of. What needs to be 
clear is that there are specific duties associated with research in vulnerable populations and the 
burdens of these duties must be shared amongst actors in a clinical trial. While some of the above 
recommendations may be aspirational, the urgency with which we need vaccines and therapeutics 
to target diseases burdening those living in low-resource settings does not justify relaxing ethical 
standards. The answer is not in banning these trials, as we need to develop tools to tackle diseases 
endemic to populations in low-resource settings. The answer is also not in removing the free 
medical care, as the validity of the science requires healthy children and not acting to reduce the 
number of preventable deaths counteracts the foundational principle of beneficence (preventing 
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harm). Where we must focus our attention is protecting autonomy and enhancing choice within 
the boundaries of the clinical trials. It is unfair to the frontline researchers to not the outline medical 
care obligations of the sponsors in detail and proportional to the local structures available, this 
leaves them without the means to address the structural inequities (Georgetown University 
Workshop on the Ancillary-Care Obligations of Medical Researchers Working in Developing 
Countries, 2008). Leaving front-line researchers ill-equipped to deal with the structural disparities 
is both inefficient and places an excessive moral weight on the researchers, instead support needs 
to be provided to frontline researchers where it is needed. To understand these needs and the 
context of these frontline researchers, I will next explore the researcher experience when working 




RESEARCHER’S EMBODIED REALITY 
 
 While community experiences are often investigated, the personal experience of the 
researcher is frequently left in the margins. This has generated frameworks outlining the what 
researchers “owe” their subjects, providing guidance without accounting for the individual story 
of the researchers (Richardson & Belsky, 2004). This reliance on a single story to paint the whole 
picture results in skewed interpretations of the contextual reality (Mkhwanazi, 2016). I was in a 
unique position in this project to gain insight into both the caregiver and the researcher experience 
in the PMVT. 
 
Moral distress  
 
 Through my interviews with the researchers a grappling reality came to light. Local 
researchers are embedded in these communities during the entire duration of these trials, in the 
case of the phase III malaria vaccine trial, five years. More so, the researchers are part of an 
institution that has ongoing research studies in the community and may spend the majority of their 
careers working with these communities. Being embedded in the community in this way has them 
balancing the professional commitment to their work and the other roles they inhabit as social 
human beings. When asking what it is like for the researcher to respond to children seeking 
treatment who are not enrolled in the trial: 
 “I feel very strange. I feel very funny. I feel cornered. I don’t know. But I can 
never let them go, I will never let them go because I am a parent, I am a 
grandparent, and I am a researcher. So I feel in all of those perspectives and I 
appreciate it when the PI allows me to let them be treated.”  
This quote reflects the moral dilemma that many researchers working in low-resource settings 
face, the inequities present and the consequence to human life as a result of the structural disparity.  
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 Earlier, we have established the importance of collaborative partnerships with local 
stakeholders to reach a consensus about the purview and degree of care to be provided by the 
clinical trial, particularly in settings with perverse structural inequity. The PMVT case study I 
investigated in this project provided care to participants beyond the scope of their research 
question, for instance providing nutritional counselling and emergency care in response to traffic 
accidents. This has also been the case for other studies in low-resource settings, for example a 
tuberculosis prevention study in South Africa provided free follow-up HIV care for participants 
and a vaginal microbicide trial in Benin provided care for the sex worker participants in cases 
where an extrauterine pregnancy was detected (Georgetown University Workshop on the 
Ancillary-Care Obligations of Medical Researchers Working in Developing Countries, 2008). 
Both of those studies were in close partnership with local stakeholders to establish reasonable 
standards of care with proportionality around both benefits and risks. However, when the scope of 
ancillary care is not clearly defined or their boundaries prevent the researcher from acting in 
alignment with their moral norms, an internal conflict is sparked in the researcher on the frontline.  
 
The duty to rescue 
 
 Australian philosopher Peter Singer proposed that we have a duty to reduce suffering and 
death whenever we can (Singer, 1972). This controversial position was further defined as helping 
those in need when no one else is able to, without significant personal sacrifice, as a universal duty 
(McIntyre, 1994). Researchers in this project have expressed their internal experience of this duty, 
in conjunction with the long-term relationship many frontline researchers have with their research 
participants and communities, as the source of their moral distress in researchers. Particularly when 
budget constraints hold them back from providing needed care for community members. This led 
to reports in the study of researchers personally financing medications for family members of 
participants and grappling with their conflicting obligations to the community and to the research 
institution. While the duty to rescue is a controversial position, the way researchers experienced 
the obligations to the community when it is within their own means, was undeniable for them. The 
long-term relationships these researchers had with community engagement practices and also their 
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own personal stories as human social beings led to conflicting obligations towards the clinical trial 




RELATIONAL ETHICS  
 
 The main shortcoming of a principalist ethical approach is that it negates to situate the 
above realities into the everyday life of the human researcher. Geissler et al. have advocated for a 
more searching and open frame of ethical rules defined by relational ethics, however they raise the 
difficulty (and perhaps danger) of abandoning formal principalist ethics and consequently relying 
on a qausi-legal frame and private morality (P. Wenzel Geissler et al., 2008). Where principal-
based ethics provides a solid foundation to guide medical research, relational ethics can 




 The introduction frames the questions around the foundational principles. Based on my 
interviews with both the researchers and participants I have come to better understand the 
multifaceted nature of clinical trial research in low-resource settings. The research protocol is 
written to adhere to scientific rigour and generate knowledge, the researchers are implementing it 
as social beings who make ethical decisions in the context of relationships, and the caregivers are 
seeking to meet their families’ needs. This leaves the researchers in the middle, with an onus of 
negotiating both their commitments to their protocol and to its subjects. Researchers in our study 
found ways to negotiate these demands and wherever possible, to meet the medical needs of the 
children in the study site. Their commitments to members of the community allowed for the 
establishment of trust, which in turn fostered the sustainability of the relationship between the 
research institution and the community. Researchers during the interviews spoke about the 
nicknames that members of the community had coined for them, with one respondent being 
referred to as “mother of the site”, showing the relational hospitality that research teams 
established beyond the requirements of the foundational principals.  
 
 Having this ethics of intimacy and relatedness can complement the foundational principals. 
As I discussed above, a particularly important aspect of strengthening autonomy is strengthening 
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the medical care options for the community. Through familial and trusting relationships 
community members can exchange in a dialogue with researchers to communicate their needs. 
This fosters the identification of health services that are needed to reduce structural disparities and 
how they can be strengthened. In turn, these researchers can situate the context in relation to the 
medical care provided by the trial and identify if there is the possibility of undue inducement as a 
result of the structural disparity and lack of choice. Relational ethics is necessary to establish the 





 Trust plays an important role in clinical trial outcomes (Enria et al., 2016; Kass, Sugarman, 
Faden, & Schoch-Spana, 1996; Kerasidou, 2017). Through research practices that broke trust, such 
as the Tuskegee syphilis study, the formal requirements concerning ethical review of research 
protocols were put into place.  When trust is broken in this way it has major implications beyond 
the scope of the individual research project and into the way those populations respond to future 
research (Kass et al., 1996). When caregivers consent to enroll their child in clinical trial research 
there is a degree of implicit trust in the research institution, the regulatory oversight and the 
researcher.  
 
 The most common link between trust and research is with regards to seeking informed 
consent for research participation (Kerasidou, 2017; V. Marsh, Kamuya, Rowa, Gikonyo, & 
Molyneux, 2008; Molyneux et al., 2005; Sugarman et al., 1998). The Nuremburg Code established 
the first guidelines around informed consent in medical research, however the role of informed 
consent in ethical medical research was recognized as early as the nineteenth century (Vollmann 
& Winau, 1996). Free and informed consent is often considered the sine qua non of good research, 
however as I discussed earlier, it is also one of the most sensitive and complex parts of clinical 
research (S. R Benatar, 2002). The researchers I interviewed expressed this link between trust, 
 133 
transparency and informing participants. They emphasize what is required to maintain trust and 
the consequences for future research in that setting when it is broken: 
 
“What is important in the community is that you must be trusted. They have to 
trust you. And in research it is good to be trusted and you need to be very 
straightforward and to the point. Because if you say the truth about a particular 
study, what procedures will be done, how long do you think they will take per 
visit, you know around about, and then what blood draws if any. You know and 
the specifics, then they will trust you and they will do that. But if you tell them one 
story and do different stories then they will never trust you and they will not 
continue coming to other studies.” 
 
 Frontline researchers reported to be very careful in communicating the details of the 
procedures and committing to transparent communication, due to the possible implications of 
broken trust down the road. While aware of this link between transparency and trust, the adept 
awareness of the relational was also a common string in the interviews. This was heavily situated 
in the context and the relationship between the researcher, the caregiver and the participant. This 
extended beyond what researchers “ought” to do as described by their professional code of 
conduct, for instance the informed consent practices, and into their own sense of the relational 
context (Participants of an International Workshop in Kenya on the Role of Frontline Staff in 
Biomedical Research, July 2014 & Kombe, 2015). The link between relational ethics and trust was 
made explicit in the following narrative told by one of the researcher respondents: 
 
 “I came in the room, I sat, and I shook her hand and I shook the baby’s hand. I 
even took the baby onto my lap. The baby even leans on me like this, so the mother 
trusts me with the baby. Then I tell her ok, and I can even sing with your name, I 
can make a quick song with your name. So she trusts, “she is really good with my 
baby, this doctor is good with my baby.” So when I give her baby back, and now 
mama so and so we are going to take a sample, remember which visit this is, then 
she will tell you “oh she forgot” and we will remind her it is visit five. Don’t be 
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in a hurry. Visit five, how much were we removing? “I forgot. But you know, I 
was told it was. Oh I was told” then you tell me “visit five we are doing a safety 
check and we are only removing this. So today we are going to remove this from 
the baby, we try to get the vein and we hope we shall find the vein once.” So just 
carry the baby like this and position the baby like this like this, then I will give her 
back her baby. You can even tell her, “eh the baby is smart, eh the baby has a 
pretty pink dress.” You know you praise her, then she believes, oh her heart 
lowers”  
 
 This narrative illustrates relational actions by the researcher and how they can influence 
the subjective experience of the caregiver. They are not restricted to the dialogic, instead the 
researcher is embodied in this interpersonal relationship and in attunement with the caregiver and 
the participant. An emotional engagement with the ‘lived life’ that fosters a trust based in the 
understanding of the caregiver and participant as individuals with unique needs (Edwards, 2005). 
Through being active in the relationships of the moment, the researcher is embedded in a relational 
context (MacDonald, 2007). Here relational ethics can provide a moral perspective that is 
supplementary to the foundational principle of beneficence, not merely dialectical, allowing for an 
engagement with the ‘lived life’ and providing a deeper ground for the roots of trust to take hold. 
This trust grows out of reflexive relational embodiment as exhibited in the narrative told by the 
researcher. The vulnerability of each actor is embraced, and the potential power differential is not 
extinguished, but acknowledged. This allows for a mutual respect to take hold which opens the 
door for the researcher to experience the caregiver’s reality and discern the context out of which 
they are making a decision. When researchers are provided with the tools to foster trust and act 
out of their embodied self, they can strengthen choice and agency in the setting by providing 
insights into the structural inequities and the ways in which to address them. However, in cases 
where researchers are not provided the tools this can lead to moral distress. The researcher then 
becomes enmeshed into the caregiver’s reality, experiencing the duty to rescue without the trial 
resources. Therefore, when asked if a researcher ever personally financed treatment upon a 
caregiver’s request this was the response:  
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“Yes, I have done that. Yes because sometimes it is terrible. The baby is going to 
die, because sometimes anemia has set in, HB is like 7, the parasitemia level has 
actually dropped to five. There is no blood transfusion because the hospitals are 
on strike. Who will transfuse them? When you get them in to the private hospital 
they will locked there without bills. So they are there to stay. And the other 
children are not being taken care of at home and they cannot go to school, they 
have nothing to eat, so it is all complicated. Because women are the ones who go 
digging to get money to come and feed the families. Maybe husbands also do small 
things but are actually not there. So when she is locked in the hospital the other 
family members are stuck. And they can’t eat, they can all be under famine, the 
five years are the one who is sick, the 4 years, the 3, 2, 1 the one she has. It is 
complicated. And it happens a lot anyway. The level of poverty, health care. They 
say healthcare is supposed to be free in this country and it doesn’t go like that 
because systems are not complete. Lab is there, you have to get the lab. Lab will 
tell you we don’t have this reagent go to another facility. Where is the transport? 
Do you walk with a sick child? They can go to the lab and do all the things and 
then take drugs in the pharmacy. But they don’t have drugs in the pharmacy. 
Coartem is not in the pharmacy, why? Because the system they have in place for 
the counties is that they cannot give coartem alone. We give you coartem supply 
with the rest of the hospital supply and it has not arrived. There is zero in the 
pharmacy. What happens? It is all complicated and very dangerous for children. 
 
 The structural disparity is witnessed and experienced by the embodied researcher, this is a 
very real reality for the researchers who are relationally deeply involved in the community during 
long-term trials.  The distress of the researchers continues when they arrive home, witnessing their 
own limitations and the realities of operating in these contexts: 
 
“You keep wondering did I really do it well at the end of the day. Because when 
you go home and sit and you now analyze how it was in the day, and it is like, 
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surely did I help that family? Did I help? It haunts you if you did not really do 
well. It makes you feel bad.” 
 
 If the researchers were only inhabiting a reality sufficiently accounted for by the 
principalist approach used to review the study protocol, this moral distress would not exist. 
However, instead they are unable to meet the demands of their professional duties and their own 
moral duties. The starkly different reality due to the (medical) structural inadequacy leaves the 
embodied researcher exposed and vulnerable. While necessary to build trust in this setting, 
reflexive relational research also calls for the researcher to drop the cloak of indifference 
(Etherington, 2007). To protect the researcher’s vulnerability and honour the participant’s and 
caregiver’s realities, the tools to act in settings with structural disparity need to available to 
frontline researchers. For this we need clearly defined roles and responsibilities corresponding to 
the actors in the trial from the very beginning of trial design. 
 
Roles and Responsibilities  
 
 We have discussed trust and how it can be defined as personal: between the researcher, 
caregiver and pediatric participant. It can also extend into the regulatory oversight and the 
institution. As I mentioned earlier, when a caregiver consents to medical research on behalf of a 
pediatric participant there is an implicit trust in the regulatory oversight. The role of the RECs to 
protect trust in the research enterprise should therefore always be taken very seriously, Kass et al. 
outlines, “those who oversee research should be humbled by the trust patient-subjects have in the 
research enterprise and should continue to do their best to live up to that trust” (Kass et al., 1996). 
Both the RECs and the sponsors detailing the protocols have a responsibility to maintain an ethic 
of trust, this is done by careful consideration of the protocol. In particular with regards to the 
contextual structural reality, situating the benefits in relation to the realities inhabited by 
participants and seeking ways in which to strengthen existing infrastructure when relevant. When 
it comes to trust and its expansion into the clinical trial, it is helpful to understand the role of each 




















































































































Determine local standard of 
care 
x x x x       
Make a decision on the 
standard of care in the clinical 
trial 
x x x x x x x x   
Receive medical care           x 
Provide financing for medical 
care for the whole community 
   x       
Provide financing for medical 
care for participants and 
provide it if a broader scope is 
necessary  
x x x x       
Provide medical care to 
participants in the trial 
     x x    
Strengthen national health 
system  
   x       
Review research protocol and 
supplementary materials 
    x      
Meet ethical standards in the 
protocol 
x x x  x x x    
Establish scientific validity x x x x x x x    
Seek informed consent      x x    
Collect the data      x x    
Improve local infrastructure x x  x       
Protect the pediatric participant x  x  x x x x x x 
Attend scheduled appointments         x x 
Engage the community      x x    
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Table 2. The roles and responsibilities of actors in a clinical trial in the context of medical 
services.  
 The roles and responsibilities outlined in Table 2 are not exhaustive for all roles associated 
with clinical trial conduct and are intended to provide guidance, they may vary depending on the 
context. They are specifically aimed at defining roles pertaining to the challenges around medical 
services offered and structural inequity in low-resource settings. Through defining the roles of 
each actor, responsibilities will not be put off until it reaches the frontline researcher, burdening 
them with unfair duties and generating internal value conflicts. By recognizing the embodied 
reality of the researcher, supporting them in building trust with the research participants, and 
sharing the burden of challenges associated with research in low-resources settings the ethical 
challenges associated with research in low-resource settings can be reduced. This leads to greater 








This establishment of the roles that each actor in the clinical trial has can facilitate three key actions 
in clinical trial design: 
 
1) Recognize the role of the frontline researchers and the tools they need to build trust with 
caregivers and the community. 
 
2) Identify ways in which to support front line researchers in a way that is appropriate for 
the context and its structural capacity. 
 
3) Develop collaborative partnerships with local stakeholders to reduce structural 
inequities and foster sustainable health system strengthening.  
 
 These three actions will vary depending on the local context of the clinical trial, making it 
important to apply them in collaboration with the simple rules outlined in Communities and 
clinical trials: A case study from the RTS,S malaria vaccine trials in eastern Africa. Using 
complexity theory to work in iteration with the community and caregivers will enable the 
researcher to hold a relational position that is reflexive to the unique reality of the caregiver and 
participant. As complexity theory aims to embrace the unpredictability of working in CAS, a 




Project Limitations  
 
 This thesis investigated the ethical challenges associated with clinical trial research in low-
resource settings. The empirical data was a collection of 78 interviews with caregivers of PMVT 
participants and 11 interviews with researchers working on a PMVT. There are a number of 
limitations that stem from the empirical data collection method.  
 First off, the first language of the caregivers varied depending on the site (Swahili, Dholuo, 
Lusoga, Luganda, and English). This required me work with research assistants who were fluent 
in the first language of the respondent and thereby provide me with translations. The research 
assistants were also not inhabitants of the villages where the interviews were conducted, instead 
they were coming from Kampala, Kisumu or Dar es Salaam and therefore there were cultural 
barriers for them as well. The difficulty of working with translations where linguistic and cultural 
representations are lost, results in the potential to misrepresent responses and limits the 
applicability of the findings (Squires, 2009). However, through daily field meetings discussing 
these challenges, inquiring about local slang and reflexivity on behalf of the research assistants 
and the field team, I believe the impact of translational misrepresentation is minor.  
 The interviews with the researchers provided unexpected insights into the realities that 
researchers grapple with. These interviews were limited to the sites in Kenya and not expanded 
into the PMVT in Uganda and Tanzania. This limits the generalizability of the findings and is only 
representative of the population investigated. To strengthen the data, an expansion of the study 
population in the research design would enable a wider scope of applicability for these findings.  
 This study aimed to capture the ethical challenges in low-resource settings when 
conducting clinical trials, limiting the generalizability. Through focusing on a malaria vaccine 
clinical trial and limiting it to East Africa, the corresponding findings are not applicable to all 
clinical trials in low-resource settings. Furthermore, the interviews with regards to the RTS,S 
malaria vaccine Phase III clinical trial, were conducted at three sites, with two of those being in 
Kenya. This resulted in 66% of the data being from the same geographical area and generated a 
reduced representability of the data for the Tanzanian site.   
 Finally, the interviews took place between from 3-5 years since the trial had taken place in 
the communities of the caregivers. This limited respondent recall as many events had taken place 
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in their life since the trial. This was addressed by formulating questions to promote recall and 
events that took place during that time and focused on the individual’s account of the experience 




Implications for Future Research 
 
 Through the elucidation of factors impacting the choice to participate in research, the 
realities of frontline researchers and the ways in which responsibilities can be shared across 
stakeholders in clinical trials this study contributes to the ways in which ethical challenges can be 
addressed in research design. Future research focusing on the different countries outside of the 
East African setting investigated here can provide a more expansive interpretation of the findings 
and strengthen the generalizability. Tied to this, assessing the applicability of the simple rules 
outlined in this thesis as well as their impact on caregiver choice would contribute greatly to the 
overall understanding of how to enable research teams to work in iteration during their engagement 
with the community. Therefore, future research investigating the impact of these rules through 
both qualitative interviews and quantitative assessments (eg. survey) of the community acceptance 
of research would be of great benefit.  
 In large part, this research should not focus on creating new requirements for research 
teams, instead equip them with the tools necessary to flourish in the existing system and readily 
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Ethical Implications of the Malaria Vaccine Development 
 
 
Informed consent form caregivers 
_______________________________________________________________________________ 
 
Part I: Information Sheet  
 
Introduction  
I am Machteld van den Berg, a student at the Swiss Tropical and Public Health Institute. I am doing 
research that relates to ethical implications on malaria vaccine. I am going to give you information 
which will enable you make decision on whether to participate in this research. You do not have to 
decide today whether or not you will participate in the research. Before you decide, you can talk to 
anyone you feel comfortable with about the research. 
This consent form may contain words that you do not understand. Please ask me or stop as we go 
through the information and I will take time to explain. If you have questions later, you can ask them.  
 
Purpose of the research  
Malaria is a very common disease in this country and in sub-Saharan Africa which makes many people 
particularly children sick. Despite existing strategies to combat malaria in your community, we would 
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like to make further improvement and discourage disease transmission and associated deaths. We 
believe that you can help us doing this by telling us what you know both about malaria and about a 
vaccine that was tested against it. We want to learn what people who live here know about the causes 
of malaria and the things you do to stop yourself and your children from getting malaria. We want to 
know these things because this knowledge might help us to learn how we can better control malaria in 
your community.  
 
Participant Selection  
You are being invited to take part in this research because we think that your experience as a mother 
can contribute much to our understanding and knowledge of local health practices and beliefs.  
 
Voluntary Participation  
Your participation in this research is entirely voluntary. It is your choice whether to participate or not. 
The choice that you make will have no bearing on your job or on any work-related evaluations or 
reports. You may change your mind later and stop participating even if you agreed earlier. 
 
Research procedures  
A. We are asking you to participate in research. If you accept, you will be asked to indicate your 
consent in the informed consent form. Thereafter you will take part in an interview with us which 
will take about one hour.   
 
B.  Interviews with myself and a local translator.  
During the interview, we will sit down with you in a comfortable privacy place. If it is better for 
you, the interview can take place in your home or a friend's home. You will be requested to answer 
a series of questions during the interview. The interviewer will move from one question to the next 
question. There will be no wrong response. Every response will be valued. No one else but the 
interviewer will be present. The information recorded is confidential, and no one else except the 
project leader and research assistant will access the information documented during your 
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interview. The entire interview will be tape-recorded based on your consent, but no-one will be 
identified by name on the tape. The tape will be kept secured in the office. The information 
recorded is confidential, and no one else except the research assistant and myself will have access 
to the tapes. The tapes will be destroyed after 1 year. 
 
Duration  
We will conduct one interview and the interview will take about 1 hour.  
 
Risks  
There is a risk that you may share some personal or confidential information by chance, or that you 
may feel uncomfortable talking about some of the topics. However, we will ensure an intense 
confidential of information that you provide. You do not have to answer any question or take part in 
the interview if you feel the question(s) are too personal or if talking about them makes you 
uncomfortable. We will also try as much as possible not to make the interview long unnecessary. 
 
Benefits  
There will be no direct benefit to you, but your participation is likely to help us find out more about 
how to improve malaria prevention strategies in your community. 
 
Reimbursements 
There will be a payment of 200 Kenyan Shillings as compensation for your time. 
 
Confidentiality of Information 
The research being done in the community may draw attention and if you participate you may be asked 
questions by other people in the community. We will not be sharing information about you to anyone 
outside of the research team. The information that we collect from this research project will be kept 
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private. Any information about you will have a number on it instead of your name. Only the researchers 
will know what your number is and we will lock that information up with a lock and key.  
 
Nothing that you tell us today will be shared with anybody outside the research team, and nothing will 
be attributed to you by name. The knowledge that we get from this research will be shared with you 
and your community before it is made widely available to the public. Following the meetings, we will 
publish the results so that other interested people may learn from the research. 
 
Right to Refuse or Withdraw  
You do not have to take part in this research if you do not wish to do so, and choosing to participate 
will not affect your access child’s access to vaccination in the future. You may stop participating in the 
interview at any time that you wish. I will give you an opportunity at the end of the interview to review 
your remarks, and you can ask to modify or remove portions of those, if you do not agree with my 
notes or if I did not understand you correctly.  
  
Who to Contact 
If you have any questions, you can ask them now or later. If you wish to ask questions later, you may 
contact any of the following: Ms. Florence Were fachieng@kemricdc.org number 720 251 082; 
Machteld van den Berg, machteld.vandenberg@uzh.ch, +41 077 414 0594. If you have questions that 
relates to ethical issues you may contact the IHI-IRB administrator:  
 
 
Part II: Certificate of Consent  
 




I have read the foregoing information, or it has been read to me. I have had the opportunity to 
ask questions about it and any questions I have been asked have been answered to my 
satisfaction. I consent voluntarily to be a participant in this study  
 
 
Print Name of Participant__________________     
Signature of Participant ___________________ 
Date ___________________________ 
 Day/month/year    
 
If illiterate 1 
 
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
 
Print name of witness____________       Thumb print of participant 
Signature of witness    _____________ 
Date ________________________ 
                Day/month/year 
    
Statement by the researcher/person taking consent 
 
                                                 
1 A literate witness must sign (if possible, this person should be selected by the participant and should have no connection to the 




I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that the following will be done: 
- A one hour interview discussing malaria perception and vaccination experience 
 
I confirm that the participant was given an opportunity to ask questions about the study, and all 
the questions asked by the participant have been answered correctly and to the best of my ability. 
I confirm that the individual has not been coerced into giving consent, and the consent has been 
given freely and voluntarily.  
   
A copy of this ICF has been provided to the participant. 
Print Name of Researcher/person taking the consent________________________   
  
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________    








My name is Machteld van den Berg and I am a student from Switzerland studying malaria. I am 
interested in learning more about your experience with malaria and the vaccine.  
Is it alright for you if I record the interview? No one except myself, the research assistant will 
have access to the recording and if you decide that you would like me to delete the recording, I 
will do this.  
 




1. What do you understand about malaria disease? What is the sickness? 
Prompt: Can you describe the disease to me? 
How do people behave? How do people get healthy again? 
Is it the same with children? 
 
2. What sorts of things should you do so you do not get malaria? 
 
3. What do you do if someone has a fever? How do you know if it is Malaria? 
Probe: can the clinic here help? 
 





5. Where do the people take their children to get their vaccinations? 
Probe: does this stop them from getting sick? 
What do you think this does? 
 
6. What was the condition of the child after receiving the malaria vaccine? 
Prompt: Can you describe the changes? 
 
7. What is the function of the malaria vaccine? 
Probe: does your child still need a bed net? Why does the child still use a 
bed net or why not?  
Do you think people will behave differently if their child is vaccinated? 
Can your child still get malaria? 
 
8. Was the malaria trial different from when you take your child to the clinic for other 
routine vaccines? 
Probe: If so, How?  
 
EXPERIENCE WITH RESEARCH STUDY 
 
9. What is your opinion on the way the vaccine is provided to your child?  
 
10. What do you think it was like for your child to get the malaria vaccine? 
Prompt: how did they behave? Was your child comfortable? 
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Probe: Do the parents feel comfortable? 
 
11. Do you think this malaria study was a good one?  
Prompt: things you liked or did not like.  
What encouraged you to participate?  
Could you ask questions if you didn’t understand something? 





12. Do you think people in your community would get the vaccine if it becomes available in 
your community in the future? 
Probe: Do you think the malaria vaccine should be scaled up? 
Would people be willing to pay a little bit for it? 
Why only children under 5? 
 
13. Do you like the idea of having something like this in the community?  
Probe: Why do you think only small children get it? 
 
14. Is there anything else you think about this vaccine? 
 
15. Is there anything else you would like to add or ask me? 
 
Thank you for your time and help.  
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Ethical Implications of the Malaria Vaccine Development 
 
 
Informed consent form researchers 
_______________________________________________________________________________ 
 
Part I: Information Sheet  
 
Introduction  
I am Machteld van den Berg, a student at the Swiss Tropical and Public Health Institute. I am doing 
research that relates to ethical implications on malaria vaccine. I am going to give you information 
which will enable you make decision on whether to participate in this research. You do not have to 
decide today whether or not you will participate in the research. Before you decide, you can talk to 
anyone you feel comfortable with about the research. 
This consent form may contain words that you do not understand. Please ask me or stop as we go 
through the information and I will take time to explain. If you have questions later, you can ask them.  
 
Purpose of the research  
Malaria is a very common disease in this country and in sub-Saharan Africa which makes many people 
particularly children sick. Despite existing strategies to combat malaria in your community, we would 
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like to make further improvement and discourage disease transmission and associated deaths. We 
believe that you can help us doing this by telling us what you know both about malaria and about a 
vaccine that was tested against it. We want to learn what researchers think about how malaria vaccines 
are developed and how to improve the process.  
 
Participant Selection  
You are being invited to take part in this research because we think that your experience as a researcher 
can contribute much to our understanding and knowledge of malaria vaccine development.  
 
Voluntary Participation  
Your participation in this research is entirely voluntary. It is your choice whether to participate or not. 
The choice that you make will have no bearing on your job or on any work-related evaluations or 
reports. You may change your mind later and stop participating even if you agreed earlier. 
 
Research procedures  
B. We are asking you to participate in research. If you accept, you will be asked to indicate your 
consent in the informed consent form. Thereafter you will take part in an interview with us which 
will take about one hour.   
 
B.  Interviews with myself and a local translator.  
During the interview, we will sit down with you in a comfortable privacy place. If it is better for 
you, the interview can take place in your home or a friend's home. You will be requested to answer 
a series of questions during the interview. The interviewer will move from one question to the next 
question. There will be no wrong response. Every response will be valued. No one else but the 
interviewer will be present. The information recorded is confidential, and no one else except the 
project leader and research assistant will access the information documented during your 
interview. The entire interview will be tape-recorded based on your consent, but no-one will be 
identified by name on the tape. The tape will be kept secured in the office. The information 
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recorded is confidential, and no one else except the research assistant and myself will have access 
to the tapes. The tapes will be destroyed after 1 year. 
 
Duration  
We will conduct one interview and the interview will take about 1 hour.  
 
Risks  
There is a risk that you may share some personal or confidential information by chance, or that you 
may feel uncomfortable talking about some of the topics. However, we will ensure an intense 
confidential of information that you provide. You do not have to answer any question or take part in 
the interview if you feel the question(s) are too personal or if talking about them makes you 
uncomfortable. We will also try as much as possible not to make the interview long unnecessary. 
 
Benefits  
There will be no direct benefit to you, but your participation is likely to help us find out more about 
how to improve malaria prevention strategies in your community. 
 
Confidentiality of Information 
We will not be sharing information about you to anyone. The information that we collect from this 
research project will be kept private. Any information about you will have a number on it instead of 
your name. Only the researchers will know what your number is and we will lock that information up 
with a lock and key.  
 
Nothing that you tell us today will be shared with anybody outside the research team, and nothing will 
be attributed to you by name. The knowledge that we get from this research will be shared with you 
and your community before it is made widely available to the public. Following the meetings, we will 
publish the results so that other interested people may learn from the research. 
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Right to Refuse or Withdraw  
You do not have to take part in this research if you do not wish to do so, and choosing to participate 
will not affect your prospects as a researcher. You may stop participating in the interview at any time 
that you wish. I will give you an opportunity at the end of the interview to review your remarks, and 
you can ask to modify or remove portions of those, if you do not agree with my notes or if I did not 
understand you correctly.  
  
Who to Contact 
If you have any questions, you can ask them now or later. If you wish to ask questions later, you may 
contact any of the following: Ms. Florence Were fachieng@kemricdc.org number 720 251 082; 
Machteld van den Berg, machteld.vandenberg@uzh.ch, +41 077 414 0594. If you have questions that 




Part II: Certificate of Consent  
 
I have been invited to participate in research about malaria and my experience as a researcher. 
 
I have read the foregoing information, or it has been read to me. I have had the opportunity to 
ask questions about it and any questions I have been asked have been answered to my 
satisfaction. I consent voluntarily to be a participant in this study  
 
 
Print Name of Participant__________________     
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Signature of Participant ___________________ 
Date ___________________________ 
 Day/month/year    
 
If illiterate 2 
 
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
 
Print name of witness____________       Thumb print of participant 
Signature of witness    _____________ 
Date ________________________ 
                Day/month/year 
    
Statement by the researcher/person taking consent 
 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that the following will be done: 
- A one hour interview discussing malaria and my experience as a researcher  
 
I confirm that the participant was given an opportunity to ask questions about the study, and all 
the questions asked by the participant have been answered correctly and to the best of my ability. 
                                                 
2 A literate witness must sign (if possible, this person should be selected by the participant and should have no connection to the 




I confirm that the individual has not been coerced into giving consent, and the consent has been 
given freely and voluntarily.  
   
A copy of this ICF has been provided to the participant. 
 
Print Name of Researcher/person taking the consent________________________   
  
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________    









My name is Machteld van den Berg and I am a student from Switzerland studying malaria. I am 
interested in learning more about your experience as researcher involved in RTS,S malaria 
vaccine phase III clinical trial. 
Is it alright for you if I record the interview? No one except myself will have access to the 
recording and if you decide that you would like me to delete the recording, I will do this.  
 
Is it alright for you to start the interview? 
 
Questions  
   
1. Can you describe the key activities around community engagement that took place during the 
RTS,S phase III?  
   
2. What was your specific role and responsibility with engaging with the community in the Phase 
III study?  
   
3. How did you feel when you were a part of those activities in the community?  
What kinds of things caused joy and which caused conflict? Did anything make you feel 
uncomfortable?  
   
4. What made certain activities more helpful than others?  
Do you think there could be more exchanges? Or less?  
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 5. What was the most important contribution of community participation?  
 
6. What kinds of positive negative experiences did you have? Were they with specific groups in 
the study?  
If so, how did you feel in those situations? Did you have the tools needed to deal with them?  
   
7. Are there meaningful exchanges happening? In what ways were they helpful?  
   
8. What kinds of questions did you have mothers asking about the study? Which questions were 
easy and difficult to answer?  
   
9. In which situations did you feel the mother was not able to understand the study?  
What did you do? What could have been done to facilitate understanding?  
   
10.. What do you think can be done to improve further clinical research for malaria vaccines for 
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